|
|
|
|
|
|
|
Delaware
|
|
|
3714
|
|
|
84-1905538
|
(State or Other Jurisdiction of Incorporation or Organization)
|
|
|
(Primary Standard Industrial Classification Code Number)
|
|
|
(I.R.S. Employer
Identification Number)
|
|
|
|
|
|
|
|
|
|
|
|
Stephen C. Hinton, Esq.
Bradley Arant Boult Cummings LLP
ONE 22 ONE
1221 Broadway
Nashville, Tennessee 37203
Telephone: (615) 244-2582
|
|
|
Leslie Marlow, Esq.
Patrick Egan, Esq.
Blank Rome LLP
1271 Avenue of the Americas
New York, NY 10020
Telephone: (212) 885-5358
|
|
|
|
|
|
|
|
|
Large accelerated filer ☐
|
|
|
Accelerated filer ☐
|
Non-accelerated filer ☒
|
|
|
Smaller reporting company ☒
|
|
|
|
Emerging growth company ☐
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Per Share and
Accompanying Warrant
|
|
|
Per Pre-Funded Warrant and
Accompanying Warrant
|
|
|
Total(2)
|
Public offering price
|
|
|
$
|
|
|
$
|
|
|
$
|
Placement Agent fees(1)
|
|
|
$
|
|
|
$
|
|
|
$
|
Proceeds to us, before expenses
|
|
|
$
|
|
|
$
|
|
|
$
|
(1)
|
We have agreed to pay the Placement Agent a cash fee equal to seven percent (7%) of the aggregate gross proceeds raised in
this offering. In addition, we have agreed to reimburse certain expenses of the Placement Agent in connection with this offering and to issue to the Placement Agent, or its designees, placement agent warrants (the “Placement Agent
Warrants”) to purchase an amount equal to five percent (5%) of the aggregate number of shares of Common Stock and Pre-Funded Warrants, if any, sold by us in this offering. The Placement Agent Warrants are immediately exercisable for a
period of five years at an exercise price equal to 110% of the public offering price per share of Common Stock and accompanying Warrant. See “Plan of Distribution” on page 103.
|
(2)
|
The above summary of offering proceeds does not give effect to any proceeds from the exercise of any warrants being issued in
this offering.
|
•
|
Momentus’ strategy, future operations, projected capital resources and financial position, estimated revenues and losses,
projected costs and capital expenditures, prospects, and plans;
|
•
|
the potential future capabilities of Momentus’ technology, including its water plasma propulsion technology;
|
•
|
projections of market growth and size;
|
•
|
anticipated progress and timeline of any testing of Momentus’ technology and any launch status of Momentus’ satellite
transportation systems;
|
•
|
expansion plans and opportunities; and
|
•
|
the outcome of any known and unknown litigation and regulatory proceedings.
|
•
|
the ability of the Company to finance its operations;
|
•
|
the ability of the Company to obtain licenses and government approvals for its missions, which are essential to its
operations;
|
•
|
the ability of the Company to effectively market and sell satellite transport services and planned in-orbit services;
|
•
|
the ability of the Company to protect its intellectual property and trade secrets;
|
•
|
the development of markets for satellite transport and in-orbit services;
|
•
|
the ability of the Company to develop, test and validate its technology, including its water plasma propulsion technology;
|
•
|
delays or impediments that the Company may face in the development, manufacture and deployment of next generation satellite
transport systems;
|
•
|
the ability of the Company to convert backlog or inbound inquiries into revenue;
|
•
|
changes in applicable laws or regulations and extensive and evolving government regulations that impact operations and
business, including export control license requirements;
|
•
|
the ability to attract or maintain a qualified workforce with the required security clearances and requisite skills;
|
•
|
level of product service or product or launch failures or delays that could lead customers to use competitors’ services;
|
•
|
investigations, claims, disputes, enforcement actions, litigation and/or other regulatory or legal proceedings;
|
•
|
the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and/or
|
•
|
other risks and uncertainties described in this prospectus, including those under the section titled “Risk Factors.”
|
•
|
If we fail to comply with the continued listing requirements of Nasdaq we face possible delisting.
|
•
|
You may not agree with how we use the proceeds, and the proceeds may not be invested successfully.
|
•
|
Future sales and issuances of the Common Stock could cause our stock price to fall.
|
•
|
This is a reasonable best efforts offering, with no minimum amount of securities required to be sold.
|
•
|
You will experience immediate and substantial dilution as a result of this offering and may experience additional dilution
in the future.
|
•
|
We need additional capital and any additional capital we seek may not be available in the amount or at the time we need it.
|
•
|
There is no public market for the Pre-Funded Warrants or the Warrants being offered in this offering.
|
•
|
Significant holders or beneficial holders of the Common Stock may not be permitted to exercise Warrants that they hold.
|
•
|
Significant holders or beneficial holders of the Common Stock may not be permitted to exercise Pre-Funded Warrants that
they hold.
|
•
|
The Pre-Funded Warrants and Warrants are speculative in nature.
|
•
|
Purchasers who purchase our securities in this offering pursuant to a securities purchase agreement may have rights not
available to other purchasers.
|
•
|
We may be unable to raise additional capital needed to execute our business plan.
|
•
|
We may be unable to successfully market and sell small satellites to government and commercial customers in sufficient
quantity to support our business plan.
|
•
|
Setbacks in the development, testing, and production of new satellites, as well as potential setbacks during missions to
operate or place in orbit satellites and related technologies such as solar arrays could have a material adverse effect on our business, financial condition, and results of operation and could harm our reputation.
|
•
|
We may not receive all required governmental licenses and approvals.
|
•
|
We have incurred significant losses since inception, we expect to incur losses in the future and we may not be able to
achieve or maintain profitability.
|
•
|
We will require substantial additional funding to finance our operations, but adequate additional financing may not be
available when we need it, on acceptable terms or at all.
|
•
|
We may not be successful in developing new technology, and the technology we are successful in developing may not meet the
needs of our customers or potential new customers.
|
•
|
The market for in-space infrastructure services has not been established with precision, and may grow more slowly than
expected.
|
•
|
The cyclical nature of the space industry could negatively impact our ability to accurately forecast customer demand. We
may not be able to maintain adequate gross margins or profits in these markets.
|
•
|
We are dependent on third-party launch vehicles to launch our vehicles and customer payloads into space and any delay could
have a material adverse impact to our financial condition and results of operations.
|
•
|
We may experience a total loss of our satellites and related technologies, Orbital Service Vehicle and our customers’
payloads during the launch into space.
|
•
|
Our business involves significant risks and uncertainties that may not be covered by insurance.
|
•
|
If our spacecraft fail to operate as intended, it could have a material adverse effect on our business, financial condition
and results of operations.
|
•
|
We rely on a limited number of suppliers for certain raw materials and supplied components.
|
•
|
We expect to face intense competition in the satellite bus market, satellite transport and related services and other
services which we may develop in the space transportation industry.
|
•
|
If we fail to adequately protect our intellectual property rights or our intellectual property applications for
registration fail to become issued or registered, our competitive position could be impaired.
|
•
|
We are highly dependent on our senior management team and other highly skilled personnel.
|
•
|
Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could
cause our operating results to fall below expectations or any guidance we may provide.
|
•
|
We may not be able to currently, or in the future, continue as a going concern based upon combinations of the various risk
factors discussed in this section.
|
•
|
In the event we pursue protection under Chapters 7 or 11 of the United States Bankruptcy Code, we will be subject to the
risks and uncertainties associated with such proceedings.
|
•
|
We have substantial liquidity needs and may not be able to obtain sufficient liquidity to complete a sale of substantially
all of our assets under Section 363 of the United States Bankruptcy.
|
•
|
We are currently, and may in the future be, subject to substantial litigation, regulatory actions, government
investigations, proceedings and similar actions that could cause us to incur significant legal expenses and which could have a material adverse effect on our business, operating results or financial condition.
|
•
|
Our failure to comply with export and import control and other laws and regulations could have a material adverse effect on
our business, financial condition and results of operations.
|
•
|
Changes in U.S. government policy regarding use of commercial data, satellite launches and operations, or space
infrastructure / mission providers, or material delay or cancellation of certain U.S. government programs, may have a material adverse effect on our business.
|
•
|
Contracts with the U.S. government subject us to risks including early termination, audits, investigations, sanctions and
penalties.
|
•
|
The market price of our Common Stock and warrants may be volatile, which could cause the value of your investment to
decline.
|
•
|
Our charter documents and Delaware law could prevent a takeover that stockholders consider favorable and could also reduce
the market price of the Common Stock.
|
•
|
1,071,429 shares of Common Stock issuable upon the exercise of the September Warrants, and 35,716 shares of Common Stock
issuable upon the exercise of the Placement Agent Warrants issued in connection with the September Offering;
|
•
|
357,143 shares of Common Stock issuable upon the exercise of the Investor Warrants;
|
•
|
733,101 shares of Common Stock issuable upon the exercise of the SIV Warrants;
|
•
|
28,572 shares of Common Stock issuable upon the exercise of the Lender Warrants;
|
•
|
800,000 shares of Common Stock issuable upon the exercise of the December Offering Warrants, and 40,000 shares of Common
Stock issuable upon the exercise of the Placement Agent Warrants issued in connection with the December Offering;
|
•
|
16,104 shares of Common Stock issuable upon the exercise of outstanding private placement warrants to purchase shares of
Common Stock at an exercise price of $8,050 per share;
|
•
|
12,322 shares of Common Stock issuable upon the exercise of outstanding publicly traded warrants to purchase shares of
Common Stock at an exercise price of $8,050 per share;
|
•
|
561 shares of Common Stock issuable upon the exercise of outstanding options to purchase the Common Stock granted under the
Momentus Inc. Amended and Restated 2018 Stock Plan and the Space Apprentices Enterprise Inc. 2018 Stock Plan (the “Prior Stock Plans”);
|
•
|
4,131 shares of Common Stock subject to unvested restricted stock units, 662 shares of Common Stock subject to vested
deferred restricted stock units, 827 shares of Common Stock issuable upon the exercise of outstanding options to purchase the Common Stock, and 23,313 shares of the Common Stock reserved for future grants under the Momentus Inc. 2021
Equity Incentive Plan (the “2021 Plan”);
|
•
|
5,960 shares of Common Stock reserved for purchases under the Momentus Inc. 2021 Employee Stock Purchase Plan (the “ESPP”);
and
|
•
|
1,049 shares of Common Stock subject to unvested restricted stock units and 8,289 shares of the Common Stock reserved for
future grants under the Momentus Inc. 2022 Inducement Equity Plan (the “2022 Plan”).
|
•
|
actual or anticipated fluctuations in our quarterly financial results or the quarterly financial results of companies
perceived to be similar to us;
|
•
|
changes in the market’s expectations about our operating results;
|
•
|
the public’s reaction to our press releases, our other public announcements and our filings with the SEC;
|
•
|
speculation in the press or investment community;
|
•
|
actual or anticipated developments in our business or our competitors’ businesses or the competitive landscape generally;
|
•
|
our operating results failing to meet the expectation of securities analysts or investors in a particular period;
|
•
|
changes in financial estimates and recommendations by securities analysts concerning us or the market in general;
|
•
|
operating and stock price performance of other companies that investors deem comparable to us;
|
•
|
publications of research reports by securities analysts about us, our competitors, or the space industry;
|
•
|
changes in laws and regulations affecting our business;
|
•
|
commencement of, or involvement in, litigation involving us;
|
•
|
changes in our capital structure, such as future issuances of securities or the incurrence of additional debt;
|
•
|
the volume of Class A common stock available for public sale;
|
•
|
any major change in our board of directors or management;
|
•
|
sales of substantial amounts of Class A common stock by directors, officers or significant stockholders or the perception
that such sales could occur;
|
•
|
general economic and political conditions such as recessions, interest rates, fuel prices, trade wars, pandemics, epidemics,
currency fluctuations and acts of war or terrorism; and
|
•
|
other risk factors listed under this “Risk Factors” section.
|
•
|
timing in finalizing satellite and Orbital Service Vehicle design and specifications;
|
•
|
successful completion of test programs and demonstration missions;
|
•
|
whether we will receive and the timing of receipt of licenses and government approvals that will allow us to fly our vehicles
in space and gather valuable data that will assist in further development of our vehicles;
|
•
|
meeting stated technological objectives and goals for the design on time, on budget and within target cost objectives;
|
•
|
our ability to obtain additional applicable approvals, licenses or certifications from regulatory agencies and maintaining
current approvals, licenses or certifications;
|
•
|
our ability to secure slots on our launch providers’ manifests;
|
•
|
performance of our manufacturing facility despite risks that disrupt productions, such as natural disasters;
|
•
|
performance of a limited number of suppliers for certain raw materials and supplied components and their willingness to do
business with us;
|
•
|
performance of our third-party contractors that support our research and development activities;
|
•
|
our ability to protect our intellectual property critical to the design and function of our transport vehicles; and
|
•
|
our ability to continue funding and maintaining our research and development activities.
|
•
|
forecast revenue and budget for and manage expenses;
|
•
|
attract new customers and retain existing customers;
|
•
|
effectively manage growth and business operations, including planning for and managing capital expenditures for current and
future vehicles and services, and managing the supply chain and supplier relationships related to current and future vehicles and services;
|
•
|
comply with existing and new or modified laws and regulations applicable to our business, including export control
regulations;
|
•
|
anticipate and respond to macroeconomic changes and changes in the markets in which we operate;
|
•
|
maintain and enhance the value of our reputation and brand;
|
•
|
develop and protect intellectual property; and
|
•
|
integrate and retain talented people at all levels of our organization.
|
•
|
our ability to successfully test and validate our technology, including through demonstration missions;
|
•
|
the number and weight of payloads we are able to schedule for launch during a period;
|
•
|
unexpected weather patterns, natural disasters or other events that force a cancellation or rescheduling of launches;
|
•
|
launch vehicle failures which result in cancellation or rescheduling of future launches;
|
•
|
the availability and cost of raw materials or supplied components critical for the manufacture and operation of our vehicles;
|
•
|
developments involving our competitors;
|
•
|
changes in governmental regulations or in the status of our regulatory approvals or applications;
|
•
|
future accounting pronouncements or changes in our accounting policies; and
|
•
|
general market conditions and other factors, including factors unrelated to our operating performance or the operating
performance of our competitors.
|
•
|
On September 6, 2019, the Company notified the OEE of BIS via an Initial Notice of Voluntary Disclosure that it was possible
that various unauthorized deemed exports of EAR-controlled technology to employees of the Company may have occurred. The Company completed a full audit of its trade compliance program at the time and identified several violations which
related to the apparently unintentional and unauthorized disclosure of certain limited export-controlled data to non-U.S. employees of the Company. Additional compliance protocols were implemented as part of an internal corrective
action process. This disclosure was closed by BIS pursuant to a Warning Letter dated April 20, 2020.
|
•
|
On May 5, 2021, the Company notified OEE via an Initial Notice of Voluntary Disclosure that a Momentus employee may have
inadvertently exported an email containing EAR-controlled technology to a German firm engaged in certain design work without required export authorization. The Company submitted the Germany-related final report to BIS on October 28,
2021. This disclosure was closed by BIS pursuant to a Warning Letter dated April 8, 2022.
|
•
|
On June 11, 2021, the Company notified OEE via an Initial Notice of Voluntary Disclosure that Momentus may have inadvertently
exported various EAR-controlled hardware to Poland, Singapore, Norway, and Italy without required export authorization. The Company submitted a final report on the matter to BIS on July 29, 2022.
|
•
|
specialized disclosure and accounting requirements unique to government contracts;
|
•
|
financial and compliance audits that may result in potential liability for price adjustments, recoupment of government funds
after such funds have been spent, civil and criminal penalties, or administrative sanctions such as suspension or debarment from doing business with the U.S. government;
|
•
|
public disclosures of certain contract and company information; and
|
•
|
mandatory socioeconomic compliance requirements, including labor requirements, non-discrimination and affirmative action
programs and environmental compliance requirements.
|
•
|
a classified Board of Directors whose members serve staggered three-year terms;
|
•
|
the authorization of “blank check” preferred stock, which could be issued by the Board of Directors without stockholder
approval and may contain voting, liquidation, dividend and other rights superior to our Common Stock;
|
•
|
a limitation on the ability of, and providing indemnification to, our directors and officers;
|
•
|
a requirement that special meetings of our stockholders can be called only by our Board of Directors acting by a written
resolution by a majority of the directors then in office, the Chairperson of the Board of Directors, our Chief Executive Officer or our Lead Independent Director;
|
•
|
a requirement of advance notice of stockholder proposals for business to be conducted at meetings stockholders and for
nominations of candidates for election to the Board of Directors;
|
•
|
a requirement that our directors may be removed only for cause and by a two-thirds (2/3) vote of the stockholders;
|
•
|
a prohibition on stockholder action by written consent;
|
•
|
a requirement that vacancies on our Board of Directors may be filled only by a majority of directors then in office or by a
sole remaining director (subject to limited exceptions), even though less than a quorum; and
|
•
|
a requirement of the approval of the Board of Directors or the holders of at least two-thirds of our outstanding shares of
capital stock to amend our bylaws and certain provisions of our charter.
|
•
|
any derivative action or proceeding brought on behalf of the Company;
|
•
|
any action or proceeding asserting a claim of breach of a fiduciary duty owed by or any wrongdoing by any current or former
director, officer, employee or agent of the Company or any stockholder to the Company or to stockholders;
|
•
|
any action or proceeding asserting a claim against us or any current or former director, officer or other employee or any
stockholder in such stockholder’s capacity as such arising out of or pursuant to any provision of the DGCL, our second amended and restated charter as amended, or our amended and restated bylaws as amended;
|
•
|
any action or proceeding to interpret, apply, enforce or determine the validity of our second amended and restated charter
and/or our amended and restated bylaws (including any right, obligation or remedy thereunder);
|
•
|
any action or proceeding as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware; or
|
•
|
any action or proceeding asserting a claim governed by the internal affairs doctrine, in all cases to the fullest extent
permitted by law and subject to the court’s having personal jurisdiction over the indispensable parties named as defendants.
|
|
|
|
|
|
|
|
Pro Forma
As Adjusted
Amounts
|
Assumed public offering price per share
|
|
|
$6.67
|
As adjusted net tangible book value per share as of September 30, 2024
|
|
|
$(0.52)
|
Increase in as adjusted net tangible book value per share attributable to
this offering
|
|
|
$2.45
|
As adjusted net tangible book value per share after giving effect to this
offering
|
|
|
$1.93
|
Dilution in as adjusted net tangible book value per share to new
investors in this offering
|
|
|
$4.74
|
|
|
|
|
•
|
1,071,429 shares of Common Stock issuable upon the exercise of the September Warrants, and 35,716 shares of Common Stock
issuable upon the exercise of the Placement Agent Warrants issued in connection with the September Offering;
|
•
|
16,104 shares of Common Stock issuable upon the exercise of outstanding private placement warrants to purchase shares of
Common Stock at an exercise price of $8,050 per share;
|
•
|
12,322 shares of Common Stock issuable upon the exercise of outstanding publicly traded warrants to purchase shares of Common
Stock at an exercise price of $8,050 per share;
|
•
|
560 shares of Common Stock issuable upon the exercise of outstanding options to purchase the Common Stock granted under the
Momentus Inc. Amended and Restated 2018 Stock Plan and the Space Apprentices Enterprise Inc. 2018 Stock Plan (the “Prior Stock Plans”);
|
•
|
6,067 shares of Common Stock subject to unvested restricted stock units, 679 shares of Common Stock subject to vested
deferred restricted stock units, 827 shares of Common Stock issuable upon the exercise of outstanding options to purchase the Common Stock, and 23,252 shares of the Common Stock reserved for future grants under the Momentus Inc. 2021
Equity Incentive Plan (the “2021 Plan”);
|
•
|
5,954 shares of Common Stock reserved for purchases under the Momentus Inc. 2021 Employee Stock Purchase Plan (the “ESPP”);
and
|
•
|
1,664 shares of Common Stock subject to unvested restricted stock units and 8,217 shares of the Common Stock reserved for
future grants under the Momentus Inc. 2022 Inducement Equity Plan (the “2022 Plan”).
|
•
|
Satellites and Constellation Bus: Momentus offers or plans to offer production and
operation of small satellites to meet a range of defense, government, and commercial needs such as communications, tracking of missiles, remote sensing, and space domain awareness. There is a growing need for such capabilities for
defense, government, and commercial customers. Technologies used to support the Hosted Payload market are directly applicable to offering customer-owned satellites for use in constellations. Momentus is offering high-volume production
of busses, based on Vigoride’s technologies, and integrating customer’s unique
|
•
|
Satellite Technologies: Momentus is developing and plans to offer satellite
technologies such as our Tape Spring Solar Array and other components used on the Vigoride OSV. These technologies and components have been flown in space and offer important competitive advantages such as low cost and flexibility to
meet the needs of a growing market of customers who are owners and operators of satellites.
|
•
|
Space Transportation: Under this model, our customers will deliver their payload to
us a few months prior to launch for integration onto our vehicle. Once we have integrated our customers’ payloads, we then ship our vehicle, holding the customer payload, to the launch site, where it will be integrated onto the launch
vehicle. The launch vehicle then transports our vehicle to the drop-off orbit. After separation from the launch vehicle, our OSV will transport our customers’ payloads to their chosen final orbit.
|
•
|
Hosted Payload: There are a broad range of payloads, satellite components, and other
space technologies, which customers want to operate, test, or validate in space. During development of a satellite component or other system, testing and validation of performance are important, particularly in the harsh environment of
space. In other cases, customers wish to operate technologies such as solar collection and energy transmission systems in space without the expense of developing a full system that includes the satellite bus hosting these instruments.
Momentus hosted payload service allows customers to operate, test, and validate the performance of the technology or system in space at lower cost and less complexity. Momentus service offers the ability to manage the integration and
operation of these payloads in space. Additionally, Momentus is able to obtain necessary government licenses and manage the integration of these hosted payloads onto our OSV.
|
•
|
In-Orbit Servicing: We view in-orbit servicing of satellites as a growing business
opportunity. As the number of satellites in space increases, so does their need to be serviced. We plan to develop Momentus’ vehicles to be capable of performing in-orbit servicing and are pursuing development activities that support
this objective. Although we are still developing this technology, our aim is to equip future vehicles with robotic arms and an ability to maneuver in close proximity to other spacecraft and grapple, dock, or berth with them. Once fully
developed, we believe these capabilities could allow us to offer a suite of different in-orbit services, such as inspection, refueling, life extension, re-positioning, salvage missions, maintenance and repair, and de-orbiting.
|
•
|
Constellation Bus: Technologies used to support the Hosted Payload market are
directly applicable to offering customer-owned satellite busses for use in constellations. Momentus is offering high-volume production of low-cost busses, based on Vigoride’s technologies, and integrating customer’s unique payloads for
a variety of missions ranging from communications to Earth Observation. This market heavily leverages prior investments in satellite technology to access a large and growing market segment. We introduced variants of Vigoride tailored
specifically for constellation applications as M-500 and M-1000 in August 2023.
|
•
|
Focus on leveraging common technologies through modular vehicles: Momentus is
applying technologies developed on Vigoride to offer both in-space services and traditional satellite production and bus manufacturing to customers. We believe that this approach will allow us to compete across multiple markets without
dramatically increasing our development costs. This approach also allows us to offer bundled services to constellation operators and generate differentiated offerings blending traditional bus capabilities with next-generational
service-oriented features and capabilities.
|
•
|
Unique technology with patents pending: Over the past several years, we have worked
on developing our patent-pending water plasma propulsion technology, and we have designed our vehicles and services to incorporate this technology. We have also developed technologies related to space infrastructure system architectures
and low-cost solar arrays. We are in the process of creating a patent portfolio and, as of December 31, 2024, we had seven issued patents and applications for four additional patent families relating to our water plasma propulsion and
other technologies.
|
•
|
Mission-driven strategy: Momentus is a mission-driven company, which underpins our
focus on our long-term vision and aligns all of our day-to-day activities in achieving this goal. In making decisions about our vehicles, services, technologies, or sales opportunities, we attempt to align our actions with our vision
and mission. We believe this helps us make decisions quickly and move towards achieving our goal of developing Momentus as a key provider of space infrastructure services.
|
•
|
Compatibility across launch providers: We have designed and will continue to design
our future vehicles to be compatible with most launch vehicles. We believe this will give our customers flexibility around the timing and availability of launches and ensure a competitive market for our launch providers. As more rocket
operators emerge, we will work to continue to actively incorporate compatibility to increase customer accessibility.
|
•
|
Relationships with launch providers: We have relationships with several launch
providers including SpaceX, Relativity Space, United Launch Alliance (ULA), Rocket Factory Augsburg (RFA) and several
|
•
|
Experienced management team: Many of our management team members have experience in
large organizations, including the U.S. Department of Defense, Raytheon, Lockheed Martin, Maxar, and Northrop Grumman, among others. Our efficient vertical integration allows for significant cooperation and interactivity between teams.
|
•
|
timing in finalizing systems design and specifications;
|
•
|
successful completion of further test programs and demonstration missions;
|
•
|
receipt and the timing of such receipt of licenses and government approvals that will allow us to fly our vehicles in space
and gather valuable data that will assist in further development of our vehicles;
|
•
|
meeting stated technological objectives and goals for the design on time, on budget and within target cost objectives;
|
•
|
our ability to obtain additional applicable approvals, licenses or certifications from regulatory agencies and maintaining
current approvals, licenses or certifications;
|
•
|
our ability to secure slots on our launch providers’ manifests;
|
•
|
performance of our manufacturing facility despite risks that disrupt productions, such as natural disasters;
|
•
|
performance of our third-party contractors that support our research and development activities;
|
•
|
performance of a limited number of suppliers for certain raw materials and supplied components and their willingness to do
business with us;
|
•
|
our ability to protect our intellectual property critical to the design and function of our OSVs;
|
•
|
our ability to continue funding and maintaining our current research and development activities.
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
Three Months Ended
September 30,
|
|
|
|
|
|
|
|||
(in thousands)
|
|
|
2024
|
|
|
2023
|
|
|
$ Change
|
|
|
% Change
|
Service revenue
|
|
|
$107
|
|
|
$339
|
|
|
$(232)
|
|
|
(68%)
|
Cost of revenue
|
|
|
66
|
|
|
119
|
|
|
(53)
|
|
|
(45%)
|
Gross profit
|
|
|
41
|
|
|
220
|
|
|
(179)
|
|
|
(81%)
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses
|
|
|
2,205
|
|
|
5,992
|
|
|
(3,787)
|
|
|
(63%)
|
Selling, general and administrative expenses
|
|
|
5,429
|
|
|
9,294
|
|
|
(3,865)
|
|
|
(42%)
|
Total operating expenses
|
|
|
7,634
|
|
|
15,286
|
|
|
(7,652)
|
|
|
(50%)
|
Loss from operations
|
|
|
(7,593)
|
|
|
(15,066)
|
|
|
7,473
|
|
|
(50%)
|
Other income (expense), net:
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in fair value of warrant liability
|
|
|
—
|
|
|
221
|
|
|
(221)
|
|
|
(100%)
|
Realized loss on disposal of assets
|
|
|
(133)
|
|
|
—
|
|
|
(133)
|
|
|
(100%)
|
Interest income
|
|
|
2
|
|
|
216
|
|
|
(214)
|
|
|
(99%)
|
Interest expense
|
|
|
(43)
|
|
|
(530)
|
|
|
487
|
|
|
(92%)
|
Other income
|
|
|
9
|
|
|
—
|
|
|
9
|
|
|
100%
|
Total other income (expense), net
|
|
|
(165)
|
|
|
(93)
|
|
|
(72)
|
|
|
77%
|
Net loss
|
|
|
$(7,758)
|
|
|
$(15,159)
|
|
|
$7,401
|
|
|
(49%)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
Nine Months Ended
September 30,
|
|
|
|
|
|
|
|||
(in thousands)
|
|
|
2024
|
|
|
2023
|
|
|
$ Change
|
|
|
% Change
|
Service revenue
|
|
|
$1,829
|
|
|
$2,066
|
|
|
$(237)
|
|
|
(11%)
|
Cost of revenue
|
|
|
66
|
|
|
507
|
|
|
(441)
|
|
|
(87%)
|
Gross profit
|
|
|
1,763
|
|
|
1,559
|
|
|
204
|
|
|
13%
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses
|
|
|
7,731
|
|
|
26,315
|
|
|
(18,584)
|
|
|
(71%)
|
Selling, general and administrative expenses
|
|
|
16,916
|
|
|
29,571
|
|
|
(12,655)
|
|
|
(43%)
|
Total operating expenses
|
|
|
24,647
|
|
|
55,886
|
|
|
(31,239)
|
|
|
(56%)
|
Loss from operations
|
|
|
(22,884)
|
|
|
(54,327)
|
|
|
31,443
|
|
|
(58%)
|
Other income (expense), net:
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in fair value of warrant liability
|
|
|
—
|
|
|
559
|
|
|
(559)
|
|
|
(100%)
|
Realized loss on disposal of assets
|
|
|
(188)
|
|
|
(17)
|
|
|
(171)
|
|
|
1006%
|
Interest income
|
|
|
24
|
|
|
1,128
|
|
|
(1,104)
|
|
|
(98%)
|
Interest expense
|
|
|
(100)
|
|
|
(2,182)
|
|
|
2,082
|
|
|
(95%)
|
Other income
|
|
|
61
|
|
|
20
|
|
|
41
|
|
|
205%
|
Total other income (expense), net
|
|
|
(203)
|
|
|
(492)
|
|
|
289
|
|
|
(59%)
|
Net loss
|
|
|
$(23,087)
|
|
|
$(54,819)
|
|
|
31,732
|
|
|
(58%)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
Year Ended
December 31,
|
|
|
|
|
|
|
|||
(in thousands)
|
|
|
2023
|
|
|
2022
|
|
|
$ Change
|
|
|
% Change
|
Service revenue
|
|
|
$3,089
|
|
|
$299
|
|
|
$2,790
|
|
|
933%
|
Cost of revenue
|
|
|
855
|
|
|
26
|
|
|
829
|
|
|
3188%
|
Gross profit
|
|
|
2,234
|
|
|
273
|
|
|
1,961
|
|
|
718%
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses
|
|
|
34,351
|
|
|
41,721
|
|
|
(7,370)
|
|
|
(18%)
|
Selling, general and administrative expenses
|
|
|
36,055
|
|
|
49,827
|
|
|
(13,772)
|
|
|
(28%)
|
Total operating expenses
|
|
|
70,406
|
|
|
91,548
|
|
|
(21,142)
|
|
|
(23%)
|
Loss from operations
|
|
|
(68,172)
|
|
|
(91,275)
|
|
|
23,103
|
|
|
(25%)
|
Other income (expense), net:
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in fair value of warrant liability
|
|
|
561
|
|
|
5,185
|
|
|
(4,624)
|
|
|
(89%)
|
Realized loss on disposal of assets
|
|
|
(17)
|
|
|
(168)
|
|
|
151
|
|
|
(90%)
|
Interest income
|
|
|
1,225
|
|
|
522
|
|
|
703
|
|
|
135%
|
Interest expense
|
|
|
(2,337)
|
|
|
(5,262)
|
|
|
2,925
|
|
|
(56%)
|
Litigation settlement, net
|
|
|
—
|
|
|
(4,500)
|
|
|
4,500
|
|
|
(100%)
|
Other (expense) income
|
|
|
(180)
|
|
|
54
|
|
|
(234)
|
|
|
(433%)
|
Total other income (expense), net
|
|
|
(748)
|
|
|
(4,169)
|
|
|
3,421
|
|
|
(82%)
|
Net loss
|
|
|
$(68,920)
|
|
|
$(95,444)
|
|
|
26,524
|
|
|
(28%)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
Year Ended December 31,
|
|||
(in thousands)
|
|
|
2023
|
|
|
2022
|
Net cash (used in) provided by:
|
|
|
|
|
|
|
Operating activities
|
|
|
$(61,826)
|
|
|
$(87,887)
|
Investing activities
|
|
|
(19)
|
|
|
(733)
|
Financing activities
|
|
|
1,924
|
|
|
(9,514)
|
Net change in cash, cash equivalents, and restricted cash
|
|
|
$(59,921)
|
|
|
$(98,134)
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
Nine Months Ended September 30,
|
|||
(in thousands)
|
|
|
2024
|
|
|
2023
|
Net cash (used in) provided by:
|
|
|
|
|
|
|
Operating activities
|
|
|
$(10,874)
|
|
|
$(45,987)
|
Investing activities
|
|
|
(94)
|
|
|
(7)
|
Financing activities
|
|
|
9,586
|
|
|
(5,905)
|
Net change in cash, cash equivalents, and restricted cash
|
|
|
$(1,194)
|
|
|
$(51,899)
|
|
|
|
|
|
|
|
•
|
continue to refine and operate our corporate infrastructure, people, processes and systems;
|
•
|
pursue sales and marketing activities for our product and services;
|
•
|
pursue further research and development related to developing our satellites, satellite technology, and Orbital Service
Vehicles;
|
•
|
seek regulatory approvals for operation of our satellites and vehicles;
|
•
|
actively manage our workforce, including right sizing in personnel;
|
•
|
maintain, expand and protect our intellectual property portfolio;
|
•
|
comply with public company reporting requirements; and
|
•
|
defend against litigation.
|
•
|
Identification of the contract, or contracts, with a customer.
|
•
|
Identification of the performance obligations in the contract.
|
•
|
Determination of the transaction price.
|
•
|
Allocation of the transaction price to the performance obligations in the contract.
|
•
|
Recognition of revenue when, or as, the Company satisfies a performance obligation.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Name
|
|
|
Age
|
|
|
Class
|
|
|
Current
Term
Expires
|
|
|
Position
|
|
|
Committee Membership
|
||||||||||||
|
Audit
|
|
|
Compensation
|
|
|
Disclosure
|
|
|
Nominating
and Corporate
Governance
|
|
|
Security
|
||||||||||||||
Chris Hadfield
|
|
|
65
|
|
|
II
|
|
|
2026
|
|
|
Director
|
|
|
|
|
|
*
|
|
|
*
|
|
|
*
|
|
|
|
Brian Kabot
|
|
|
47
|
|
|
I
|
|
|
2025
|
|
|
Director
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
Mitchel B. Kugler
|
|
|
64
|
|
|
I
|
|
|
2025
|
|
|
Director
|
|
|
*
|
|
|
*
|
|
|
X
|
|
|
|
|
|
|
Victorino G. Mercado
|
|
|
64
|
|
|
III
|
|
|
2027
|
|
|
Security
Director
|
|
|
|
|
|
|
|
|
|
|
|
X
|
|
|
X
|
Kimberly A. Reed
|
|
|
54
|
|
|
I
|
|
|
2025
|
|
|
Director
|
|
|
*
|
|
|
|
|
|
|
|
|
*
|
|
|
|
Linda J. Reiners
|
|
|
65
|
|
|
III
|
|
|
2027
|
|
|
Lead
Independent
Director
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
John C. Rood
|
|
|
56
|
|
|
II
|
|
|
2026
|
|
|
Chairperson
and CEO
|
|
|
|
|
|
|
|
|
*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
•
|
Class I consists of Brian Kabot, Mitchel B. Kugler and Kimberly A. Reed, whose terms will expire at the Company’s 2025 annual
meeting of stockholders;
|
•
|
Class II consists of Chris Hadfield and John C. Rood, whose terms will expire at the Company’s 2026 annual meeting of
stockholders; and
|
•
|
Class III consists of Linda J. Reiners and Victorino G. Mercado, whose terms will expire at the Company’s 2027 annual meeting
of stockholders.
|
|
|
|
|
Board Members
|
|
|
Five times the individual’s annual cash retainer (not including any
chair, lead independent director, committee or committee chair service retainers)
|
Chief Executive Officer
|
|
|
Five times the individual’s annual base salary
|
All Other Executive Officers
|
|
|
Three times the individual’s annual base salary
|
|
|
|
|
a.
|
Provide timely responses to inquiries from the CFIUS Monitoring Agencies and maintain availability, upon reasonable notice
from the CFIUS Monitoring Agencies, for discussions with the CFIUS Monitoring Agencies on matters related to the Company’s governance and compliance with the NSA;
|
a.
|
Consult with the CFIUS Monitoring Agencies on nominations to the board and exercise this authority in the Security Director’s
sole discretion, subject to such consultation with the CFIUS Monitoring Agencies; and
|
a.
|
Serve as the primary liaison between the board and the CFIUS Monitoring Agencies and provide timely responses to inquiries
from the CFIUS Monitoring Agencies and maintain availability, upon reasonable notice from the CFIUS Monitoring Agencies, for discussions with the CFIUS Monitoring Agencies on matters relating to the Company’s governance and compliance
with the NSA.
|
a.
|
appointing, compensating, retaining, evaluating, terminating and overseeing the Company’s independent registered public
accounting firm;
|
b.
|
reviewing the adequacy of the Company’s system of internal controls and the disclosure regarding such system of internal
controls contained in the Company’s periodic filings;
|
c.
|
pre-approving all audit and permitted non-audit services and related engagement fees and terms for services provided by the
Company’s independent auditors;
|
d.
|
reviewing with the Company’s independent auditors their independence from management;
|
e.
|
reviewing, recommending and discussing various aspects of the financial statements and reporting of the financial statements
with management and the Company’s independent auditors;
|
f.
|
overseeing controls governing the Company’s and its management’s public statements regarding the Company, including but not
limited to the creation of a disclosure committee; and
|
g.
|
establishing procedures for the confidential anonymous submission of concerns regarding questionable accounting, internal
controls or auditing matters.
|
a.
|
setting the compensation of the Chief Executive Officer and, in consultation with the Chief Executive Officer, reviewing and
approving the compensation, and establishing the goals and objectives, of the other executive officers of the Company;
|
b.
|
reviewing on a periodic basis and making recommendations regarding non-employee director compensation to the board;
|
c.
|
administering the Company’s cash and equity-based incentive plans that are stockholder-approved and/or where participants
include the Company’s executive officers and directors; and
|
d.
|
providing oversight of and recommending improvements to the Company’s overall compensation and incentive plans and benefit
programs.
|
a.
|
identifying, evaluating and making recommendations to the board regarding nominees for election to the Board of Directors and
its committees;
|
b.
|
considering and evaluating stockholder nominees for election to the Board of Directors;
|
c.
|
developing and making recommendations to the board regarding corporate governance and environmental, social and governance
guidelines and matters;
|
d.
|
overseeing the board’s corporate governance practices;
|
e.
|
determining the desired qualifications, expertise and characteristics for potential directors, with the goal of developing an
experienced and highly qualified board with a diverse background and skillset;
|
f.
|
overseeing the evaluation and the performance of the board and each of its committees; and
|
g.
|
contributing to succession planning.
|
a.
|
coordinating and overseeing the formulation, documentation and evaluation of the Company’s disclosure controls and
procedures;
|
b.
|
periodically reviewing and assessing the adequacy of the Company’s disclosure policy and guidelines, including without
limitation the Company’s policies regarding public disclosure of material nonpublic information; and
|
c.
|
reviewing drafts of certain of the Company’s disclosure documents.
|
|
|
|
|
|
|
|
Name
|
|
|
Age
|
|
|
Position
|
John C. Rood*
|
|
|
56
|
|
|
Chairperson, President and CEO
|
Rob Schwarz
|
|
|
56
|
|
|
Chief Technology Officer
|
Paul Ney
|
|
|
66
|
|
|
Chief Legal Officer and Corporate Secretary
|
Lon Ensler
|
|
|
66
|
|
|
Interim Chief Financial Officer
|
|
|
|
|
|
|
|
*
|
Mr. Rood is also a director of the Company, and his biographical information appears on page 80.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Name
Principal
Positions
|
|
|
Fiscal
Year
|
|
|
Salary(1)
($)
|
|
|
Bonus(2)
($)
|
|
|
Stock
Awards(3)
($)
|
|
|
Non-Equity
Incentive Plan
Compensation(4)
($)
|
|
|
All Other
Compensation(5)
($)
|
|
|
Total
($)
|
John C. Rood
Chief Executive
Officer
|
|
|
2024
|
|
|
800,000
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
119,310(6)
|
|
|
919,310
|
|
2023
|
|
|
800,000
|
|
|
80,000
|
|
|
752,094
|
|
|
800,000
|
|
|
128,175
|
|
|
2,560,269
|
||
Paul Ney
Chief Legal
Officer and Corporate Secretary
|
|
|
2024
|
|
|
450,000
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
10,907(7)
|
|
|
460,907
|
|
2023
|
|
|
450,000
|
|
|
—
|
|
|
223,838
|
|
|
247,500
|
|
|
10,349
|
|
|
931,687
|
||
Rob Schwarz
Chief Technology
Officer
|
|
|
2024
|
|
|
350,000
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
33,906(8)
|
|
|
383,906
|
|
2023
|
|
|
350,000
|
|
|
—
|
|
|
196,977
|
|
|
115,500
|
|
|
28,870
|
|
|
691,347
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
Amounts shown are amounts actually earned by the NEO during the applicable fiscal year and reflect, to the extent applicable,
any salary adjustments that occurred during the year. Amounts shown are not reduced to reflect the NEO’s contributions, if any, to the Company’s 401(k) Plan.
|
(2)
|
Amounts shown in this column represent discretionary bonus compensation amounts awarded for the applicable year of service.
|
(3)
|
Amounts in this column reflect the aggregate grant date fair value of restricted stock units (“RSUs”), as computed in
accordance with FASB ASC Topic 718. Assumptions used in the calculation of these amounts are included in Note 11 to our financial statements included in this prospectus. These amounts do not reflect the actual economic value that will
be realized by our NEOs upon the vesting of such equity awards or the sale of the common stock underlying such awards.
|
(4)
|
Represents an annual fixed bonus amount that was earned by the NEO achieving certain predetermined, measurable company
milestones for the applicable year of service.
|
(5)
|
Includes all perquisites and other personal benefits or property, “gross ups” and other amounts reimbursed during the fiscal
year and any amounts paid or accrued to any NEO pursuant to a plan or arrangement in connection with any severance obligation.
|
(6)
|
This amount includes $79,574 paid for housing expenses and $39,736 paid for employee benefits deductions for Mr. Rood
|
(7)
|
This amount constitutes employee benefits deductions for Mr. Ney.
|
(8)
|
This amount constitutes employee benefits deductions for Mr. Schwarz.
|
|
|
|
|
|
|
|
||||||||||||
|
|
|
Option Awards
|
|
|
Stock Awards
|
||||||||||||
Name
|
|
|
Number of
Securities
Underlying
Unexercised
Options
Exercisable
|
|
|
Number of
Securities
Underlying
Unexercised
Options
Unexercisable
|
|
|
Option
Exercise Price
|
|
|
Option
Expiration
Date
|
|
|
Number of
Shares or
Units That
Have Not
Vested
|
|
|
Market Value
of Shares or
Units That
Have Not
Vested(1)
|
John C. Rood
|
|
|
168(2)
|
|
|
47(2)
|
|
|
$1,778.00
|
|
|
March 20, 2032
|
|
|
1,200(2)
|
|
|
$9,516
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
318(3)
|
|
|
$2,522
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
327(4)
|
|
|
$2,593
|
Paul Ney
|
|
|
33(5)
|
|
|
3(5)
|
|
|
$1,778.00
|
|
|
March 20, 2032
|
|
|
358(5)
|
|
|
$2,831
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21(6)
|
|
|
$159
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99(7)
|
|
|
$785
|
Rob Schwarz
|
|
|
97(8)
|
|
|
12(8)
|
|
|
$1,778.00
|
|
|
March 20, 2032
|
|
|
314(8)
|
|
|
$2,490
|
|
|
|
529(10)
|
|
|
0(10)
|
|
|
|
|
|
|
|
|
80(9)
|
|
|
$634
|
|
|
|
6(11)
|
|
|
0(11)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
Amounts in this column are based upon a fair market value of $7.93 per share which was the closing price of our Class A common
stock on December 31, 2024.
|
(2)
|
Mr. Rood was granted 215 stock options on March 20, 2022, which vest in equal quarterly installments on June 20,
September 20th, December 20th and March 20th following the grant date over three years, subject to Mr. Rood’s continued employment through each such vesting date. Mr. Rood was also granted 1,800 RSUs on March 23, 2023, which vest in
three equal annual installments from the grant date, subject to Mr. Rood’s continued employment through each such vesting date.
|
(3)
|
Mr. Rood was granted 952 RSUs on March 20, 2022, which vest in three equal annual installments from the grant date, subject to
Mr. Rood’s continued employment through each such vesting date.
|
(4)
|
Mr. Rood was granted 1,309 RSUs on November 8, 2021, 6.25% of which vested on November 20, 2021, 18.75% of which vested on
August 20, 2022, and 25% of which will vest on August 20 in each of 2023, 2024 and 2025, subject to Mr. Rood’s continued employment through each such vesting date.
|
(5)
|
Mr. Ney was granted 36 stock options on March 20, 2022, which vest in equal quarterly installments on June 20th,
September 20th, December 20th and March 20th following the grant date over three years, subject to Mr. Ney’s continued employment through each such vesting date. Mr. Ney was also granted 536 RSUs on March 20, 2023, which vest in three
equal annual installments from the grant date, subject to Mr. Ney’s continued employment through each such vesting date.
|
(6)
|
Mr. Ney was granted 62 RSUs on March 20, 2022, which vest in three equal annual installments from the grant date, subject to
Mr. Ney’s continued employment through each such vesting date.
|
(7)
|
Mr. Ney was granted 393 RSUs on November 8, 2021, which vest in equal annual installments following the grant date over four
years, subject to Mr. Ney’s continued employment through each such vesting date.
|
(8)
|
Mr. Schwarz was granted 109 stock options on March 20, 2022, which vest in equal quarterly installments on June 20,
September 20th, December 20th and March 20th following the grant date over three years, subject to Mr. Schwarz’s continued employment through each such vesting date. Mr. Schwarz was also granted 471 RSUs on March 23, 2023, which vest in
three equal annual installments from the grant date, subject to Mr. Schwarz’s continued employment through each such vesting date.
|
(9)
|
Mr. Schwarz was granted 238 RSUs on March 20, 2022, which vest in three equal annual installments from the grant date, subject
to Mr. Schwarz’s continued employment through each such vesting date.
|
(10)
|
Mr. Schwarz was granted 529 stock options on February 22, 2020, 25% of which vested on February 3, 2021 and 75% of which
vested on February 3, 2024.
|
(11)
|
Mr. Schwarz was granted 6 stock options on June 15, 2020, 25% of which vested on February 3, 2021 and 75% of which vested on
February 3, 2024.
|
a.
|
All Outside Directors: $100,000
|
b.
|
Outside Director serving as Chairperson: $60,000 (in addition to above)
|
c.
|
Outside Director serving as Lead Independent Director: $30,000 (in addition to above)
|
a.
|
Member of the Audit Committee: $20,000
|
b.
|
Member of the Compensation Committee: $15,000
|
c.
|
Member of the Disclosure Committee: $15,000
|
d.
|
Member of the Nominating and Corporate Governance Committee: $10,000
|
a.
|
Chairperson of the Audit Committee: $30,000
|
b.
|
Chairperson of the Compensation Committee: $22,500
|
c.
|
Chairperson of the Disclosure Committee: $22,500
|
d.
|
Chairperson of the Nominating and Corporate Governance Committee: $15,000
|
a.
|
RSUs initially valued at $350,000 upon initial election or appointment to board, which will vest in three equal annual
installments from the date of grant; and
|
b.
|
An additional 8,572 RSUs annually (on a Post-Reverse Stock Split basis), which will vest upon the earlier of the first
anniversary of the date of grant or the day before the next annual stockholder meeting, prorated for partial years of service (including the initial year of service).
|
|
|
|
|
|
|
|
|
|
|
Name
|
|
|
Fees Earned or
Paid in Cash
($)
|
|
|
Stock Awards(1)(2)
($)
|
|
|
Total
($)
|
Brian Kabot
|
|
|
61,250
|
|
|
—
|
|
|
61,250
|
Chris Hadfield
|
|
|
70,000
|
|
|
—
|
|
|
70,000
|
Kimberly A. Reed
|
|
|
65,000
|
|
|
—
|
|
|
65,000
|
Linda J. Reiners
|
|
|
80,000
|
|
|
—
|
|
|
80,000
|
Mitchel B. Kugler
|
|
|
78,750
|
|
|
—
|
|
|
78,750
|
Victorino G. Mercado
|
|
|
82,500
|
|
|
—
|
|
|
82,500
|
|
|
|
|
|
|
|
|
|
|
(1)
|
Amounts in this column reflect compensation earned in 2024 for service as a member of the board and reflect the aggregate
grant date fair value of RSUs, as computed in accordance with FASB ASC Topic 718. Assumptions used in the calculation of these amounts are included in Note 11 to our financial statements included in this prospectus. These amounts do not
reflect the actual economic value that will be realized by our directors upon the vesting of such equity awards or the sale of the common stock underlying such awards.
|
(2)
|
During the fiscal year ended December 31, 2024, no RSUs were granted to any non-employee director.
|
|
|
|
|
|
|
|
Name and Address of Beneficial Owners
|
|
|
Number Shares of
|
|
|
%(1)
|
5% Stockholders:
|
|
|
|
|
|
|
Armistice Capital Master Fund Ltd.(2)
510 Madison Avenue, 7th Floor
New York, New York 10022
|
|
|
202,477
|
|
|
7.3%
|
Directors and Executive Officers:
|
|
|
|
|
|
|
John C. Rood
|
|
|
1,953(3)
|
|
|
*%
|
Chris Hadfield
|
|
|
74
|
|
|
*%
|
Brian Kabot
|
|
|
2,511(4)
|
|
|
*%
|
Mitchel B. Kugler
|
|
|
—
|
|
|
*%
|
Victorino G. Mercado
|
|
|
321
|
|
|
*%
|
Kimberly A. Reed
|
|
|
368
|
|
|
*%
|
Linda J. Reiners
|
|
|
368
|
|
|
*%
|
Rob Schwarz
|
|
|
901(5)
|
|
|
*%
|
Paul Ney
|
|
|
396(6)
|
|
|
*%
|
Lon Ensler
|
|
|
—
|
|
|
*%
|
Directors and executive officers as a group (10
individuals)
|
|
|
6,892
|
|
|
*%
|
|
|
|
|
|
|
|
*
|
Less than one percent.
|
(1)
|
The aggregate percentage of shares of Class A common stock reported to be beneficially owned by each person named is
determined in accordance with the rules of the SEC and is based on 2,799,881 shares of Class A common stock of the Company outstanding as of January 10, 2025.
|
(2)
|
Beneficial ownership information is based on a Schedule 13G/A filed jointly on November 14, 2024 with the SEC by Armistice
Capital, LLC and Steven Boyd, and consists of 202,477 shares of common stock beneficially owned by Armistice Capital Master Fund Ltd. Armistice Capital, LLC, in its capacity as the investment manager of Armistice Capital Master Fund
Ltd., and pursuant to an Investment Manager Agreement, has voting and investment power over the shares held by Armistice Capital Master Fund Ltd. Mr. Boyd, as the managing member of Armistice Capital, LLC, may be deemed to beneficially
own such securities. Armistice Capital Master Fund Ltd. disclaims beneficial ownership of the shares held by it, except to the extent of its pecuniary interest therein.
|
(3)
|
Consists of (i) 1,917 shares of Class A common stock and (ii) 36 shares of Class A common stock issuable upon the exercise of
options.
|
(4)
|
Represents 458 shares of Class A common stock held by Brian Kabot directly. The Schedule 13D/A filed with the SEC by
SRC-NI Holdings, LLC, the sponsor entity of Stable Road Acquisition Corp. (the “Sponsor”), on February 11, 2022 (the “Sponsor Schedule 13D/A”), indicated that Mr. Kabot, Juan Manuel Quiroga and Edward K. Freedman are the three managing
members of the Sponsor, the majority approval of whom is required to approve an action of the Sponsor. As a result, none of the aforementioned individuals are deemed to be beneficial owners of the Sponsor’s securities, which, based on
the Sponsor Schedule 13D/A, total 2,054 shares of Class A common stock in sole voting power and sole investment power. The Sponsor Schedule 13D/A specifies that the Sponsor is not a member of a group.
|
(5)
|
Consists of (i) 854 shares of Class A common stock and (ii) 47 shares of Class A common stock issuable upon the exercise of
options.
|
(6)
|
Consists of (i) 394 shares of Class A common stock and (ii) 2 shares of Class A common stock issuable upon the exercise of
options.
|
•
|
we have been or are to be a participant;
|
•
|
the amounts involved exceeded or exceeds $120,000; and
|
•
|
any of our directors, executive officers or holders of more than 5% of our outstanding capital stock, or any immediate family
member of, or person sharing the household with, any of these individuals or entities, had or will have a direct or indirect material interest.
|
•
|
250,000,000 shares of the Common Stock, $0.00001 par value per share; and
|
•
|
20,000,000 shares of undesignated Preferred Stock, $0.00001 par value per share (“Preferred Stock”).
|
•
|
prior to the date of the transaction, the board of directors of the corporation approved either the business combination or
the transaction which resulted in the stockholder becoming an interested stockholder;
|
•
|
the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction
commenced, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, (i) shares owned by persons who are directors and also officers and (ii) shares
owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or
|
•
|
at or subsequent to the date of the transaction, the business combination is approved by the board of directors of the
corporation and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least two-thirds of the outstanding voting stock that is not owned by the interested stockholder.
|
•
|
a classified board of directors whose members serve staggered three-year terms;
|
•
|
the authorization of “blank check” preferred stock, which could be issued by our board of directors without stockholder
approval and may contain voting, liquidation, dividend and other rights superior to the Common Stock;
|
•
|
a limitation on the liability of, and providing indemnification to, our directors and officers;
|
•
|
a requirement that special meetings of our stockholders can be called only by our board of directors acting by a written
resolution by a majority of our directors then in office, the Chairperson of our board of directors, our Chief Executive Officer, or our Lead Independent Director;
|
•
|
a requirement of advance notice of stockholder proposals for business to be conducted at meetings of our stockholders and for
nominations of candidates for election to our board of directors;
|
•
|
a requirement that our directors may be removed only for cause and by a two-thirds (2/3) vote of the stockholders;
|
•
|
a prohibition on stockholder action by written consent;
|
•
|
a requirement that vacancies on our board of directors may be filled only by a majority of directors then in office or by a
sole remaining director (subject to limited exceptions), even though less than a quorum; and
|
•
|
a requirement of the approval of the board of directors or the holders of at least two-thirds of our outstanding shares of
capital stock to amend our bylaws and certain provisions of our certificate of incorporation.
|
•
|
any breach of the director’s duty of loyalty to us or to our stockholders;
|
•
|
acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
|
•
|
unlawful payment of dividends or unlawful stock repurchases or redemptions; and
|
•
|
any transaction from which the director derived an improper personal benefit.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Per Share and
Accompanying
Warrants
|
|
|
Per Pre-Funded
Warrant and
Accompanying
Warrants
|
|
|
Total(2)
|
Offering price
|
|
|
$
|
|
|
$
|
|
|
$
|
Placement Agent’s fees(1)
|
|
|
$
|
|
|
$
|
|
|
$
|
Proceeds to us, before expenses
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
(1)
|
We have agreed to pay the Placement Agent a total cash fee equal to 7% of the gross proceeds of the offering.
|
(2)
|
Does not include potential proceeds from the exercise of the Warrants and/or Pre-Funded Warrants for cash, if any.
|
•
|
may not engage in any stabilization activity in connection with our securities; and
|
•
|
may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other
than as permitted under the Exchange Act, until it has completed its participation in the distribution.
|
•
|
offer for sale, sell, pledge, or otherwise transfer or dispose of (or enter into any transaction that is designed to, or
could reasonably be expected to, result in the transfer or disposition by any person at any time in the future of) any shares of Common Stock (including, without limitation, shares of Common Stock that may be deemed to be beneficially
owned and shares of Common Stock that may be issued upon exercise of any options or warrants) or securities convertible into or exercisable or exchangeable for Common Stock;
|
•
|
enter into any swap or other derivatives transaction that transfers to another, in whole or in part, any of the economic
benefits or risks of ownership of our Common Stock, whether any such transaction is to be settled by delivery of shares of the Common Stock or other securities, in cash or otherwise;
|
•
|
make any demand for or exercise any right or cause to be filed a registration statement, including any amendments thereto,
with respect to the registration of any shares of Common Stock or securities convertible into or exercisable or exchangeable for Common Stock or any other securities of the Company; or
|
•
|
publicly disclose the intention to do any of the foregoing.
|
|
|
|
|
|
|
|
Page
|
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
|
|
|
|
|
|
|
|
|
Page
|
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30,
2024
|
|
|
December 31,
2023
|
|
|
|
(unaudited)
|
|
|
|
ASSETS
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
|
$
|
|
|
$
|
Insurance receivable
|
|
|
|
|
|
|
Prepaids and other current assets
|
|
|
|
|
|
|
Total current assets
|
|
|
|
|
|
|
Property, machinery and equipment, net
|
|
|
|
|
|
|
Intangible assets, net
|
|
|
|
|
|
|
Operating lease right-of-use asset
|
|
|
|
|
|
|
Restricted cash, non-current
|
|
|
|
|
|
|
Other non-current assets
|
|
|
|
|
|
|
Total assets
|
|
|
$
|
|
|
$
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
Accounts payable
|
|
|
$
|
|
|
$
|
Accrued liabilities
|
|
|
|
|
|
|
Loan payable, current
|
|
|
|
|
|
|
Contract liabilities, current
|
|
|
|
|
|
|
Operating lease liability, current
|
|
|
|
|
|
|
Litigation settlement contingency
|
|
|
|
|
|
|
Other current liabilities
|
|
|
|
|
|
|
Total current liabilities
|
|
|
|
|
|
|
Contract liabilities, non-current
|
|
|
|
|
|
|
Warrant liability
|
|
|
|
|
|
|
Operating lease liability, non-current
|
|
|
|
|
|
|
Other non-current liabilities
|
|
|
|
|
|
|
Total non-current liabilities
|
|
|
|
|
|
|
Total liabilities
|
|
|
|
|
|
|
Commitments and Contingencies (Note 12)
|
|
|
|
|
|
|
Stockholders’ equity (deficit):
|
|
|
|
|
|
|
Preferred stock, $
|
|
|
|
|
|
|
Class A common stock, $
|
|
|
|
|
|
|
Class B common stock, $
|
|
|
|
|
|
|
Additional paid-in capital
|
|
|
|
|
|
|
Accumulated deficit
|
|
|
(
|
|
|
(
|
Total stockholders’ equity (deficit)
|
|
|
(
|
|
|
|
Total liabilities and stockholders’ equity (deficit)
|
|
|
$
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
Three Months Ended
September 30,
|
|
|
Nine Months Ended
September 30,
|
||||||
|
|
|
2024
|
|
|
2023
|
|
|
2024
|
|
|
2023
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
Cost of revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations
|
|
|
(
|
|
|
(
|
|
|
(
|
|
|
(
|
Other income (expense), net:
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in fair value of warrant liability
|
|
|
|
|
|
|
|
|
|
|
|
|
Realized loss on disposal of assets
|
|
|
(
|
|
|
|
|
|
(
|
|
|
(
|
Interest income
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
(
|
|
|
(
|
|
|
(
|
|
|
(
|
Other income
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other income (expense), net
|
|
|
(
|
|
|
(
|
|
|
(
|
|
|
(
|
Loss before income taxes
|
|
|
(
|
|
|
(
|
|
|
(
|
|
|
(
|
Net loss
|
|
|
$(
|
|
|
$(
|
|
|
$(
|
|
|
$(
|
Net loss per share, basic and diluted
|
|
|
$(
|
|
|
$(
|
|
|
$(
|
|
|
$(
|
Net loss per share, fully diluted
|
|
|
$(
|
|
|
$(
|
|
|
$(
|
|
|
$(
|
Weighted average shares outstanding, basic and
diluted
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding, fully diluted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
Common stock -
Class A
|
|
|
Additional
paid-in
capital
|
|
|
Accumulated
deficit
|
|
|
Total
stockholders’
equity (deficit)
|
|||
|
|
|
Shares
|
|
|
Amount
|
|
||||||||
Balance, December 31, 2023
|
|
|
|
|
|
$
|
|
|
$
|
|
|
$(
|
|
|
$
|
Issuance of common stock upon vesting of RSUs
|
|
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
Share repurchase related to Section 16 Officer tax
coverage exchange
|
|
|
(
|
|
|
—
|
|
|
(
|
|
|
—
|
|
|
(
|
Stock-based compensation - stock options, RSAs, RSUs
|
|
|
—
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
Issuance of common stock and related warrants in
registered offering, net of issuance costs
|
|
|
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
Issuance of common stock upon exercise of pre-funded
warrants
|
|
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
Net loss
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(
|
|
|
(
|
Balance, March 31, 2024
|
|
|
|
|
|
$
|
|
|
$
|
|
|
$(
|
|
|
$
|
Stock-based compensation - stock options, RSAs, RSUs
|
|
|
—
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
Net loss
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(
|
|
|
(
|
Balance, June 30, 2024
|
|
|
|
|
|
$
|
|
|
$
|
|
|
$(
|
|
|
$(
|
Stock-based compensation - stock options, RSAs, RSUs
|
|
|
—
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
Issuance of pre-funded warrants and warrants in
private placement, net of issuance costs
|
|
|
—
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
Issuance of common stock upon exercise of pre-funded
warrants
|
|
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
Net loss
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(
|
|
|
(
|
Balance, September 30, 2024
|
|
|
|
|
|
$
|
|
|
$
|
|
|
$(
|
|
|
$(
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
Common stock -
Class A
|
|
|
Additional
paid in
capital
|
|
|
Accumulated
deficit
|
|
|
Total
stockholders’
equity (deficit)
|
|||
|
|
|
Shares
|
|
|
Amount
|
|
||||||||
Balance, December 31, 2022
|
|
|
|
|
|
$
|
|
|
$
|
|
|
$(
|
|
|
$
|
Issuance of common stock upon exercise of stock
options
|
|
|
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
Issuance of common stock upon vesting of RSUs
|
|
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
Share repurchase related to Section 16 Officer tax
coverage exchange
|
|
|
(
|
|
|
—
|
|
|
(
|
|
|
—
|
|
|
(
|
Stock-based compensation - stock options, RSAs, RSUs
|
|
|
—
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
Issuance of common stock and related warrants in
registered offering, net of issuance costs
|
|
|
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
Issuance of common stock for consulting services
|
|
|
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
Net loss
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(
|
|
|
(
|
Balance, March 31, 2023
|
|
|
|
|
|
$
|
|
|
$
|
|
|
$(
|
|
|
$
|
Issuance of common stock upon exercise of stock
options
|
|
|
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
Issuance of common stock upon vesting of RSUs
|
|
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
Issuance of common stock upon purchase of ESPP
|
|
|
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
Issuance of common stock upon exercise of pre-funded
warrants
|
|
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
Stock-based compensation - stock options, RSAs, RSUs
|
|
|
—
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
Net loss
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(
|
|
|
(
|
Balance, June 30, 2023
|
|
|
|
|
|
$
|
|
|
$
|
|
|
$(
|
|
|
$
|
Issuance of common stock upon exercise of stock
options
|
|
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
Issuance of common stock upon vesting of RSUs
|
|
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
Share repurchase related to Section 16 Officer tax
coverage exchange
|
|
|
(
|
|
|
—
|
|
|
(
|
|
|
—
|
|
|
(
|
Issuance of common stock and related warrants in
registered offering, net of issuance costs
|
|
|
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
Issuance of common stock upon exercise of pre-funded
warrants
|
|
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
Stock-based compensation - stock options, RSAs, RSUs
|
|
|
—
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
Common stock issued in connection with reverse stock
split
|
|
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
Net loss
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(
|
|
|
(
|
Balance, September 30, 2023
|
|
|
|
|
|
$
|
|
|
$
|
|
|
$(
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
Nine Months Ended September 30,
|
|||
|
|
|
2024
|
|
|
2023
|
Cash flows from operating activities:
|
|
|
|
|
|
|
Net loss
|
|
|
$(
|
|
|
$(
|
Adjustments to reconcile net loss to net cash used in operating
activities:
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
|
|
|
|
Amortization of debt discount and issuance costs
|
|
|
|
|
|
|
Amortization of right-of-use asset
|
|
|
|
|
|
|
Change in fair value of warrant liability
|
|
|
|
|
|
(
|
Loss on disposal of fixed and intangible assets
|
|
|
|
|
|
|
Stock-based compensation expense
|
|
|
|
|
|
|
Issuance of common stock for consulting services
|
|
|
|
|
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
Accounts receivable
|
|
|
|
|
|
(
|
Prepaids and other current assets
|
|
|
|
|
|
(
|
Insurance receivable
|
|
|
(
|
|
|
|
Other non-current assets
|
|
|
(
|
|
|
|
Accounts payable
|
|
|
|
|
|
|
Accrued liabilities
|
|
|
(
|
|
|
(
|
Accrued interest
|
|
|
|
|
|
|
Other current liabilities
|
|
|
(
|
|
|
(
|
Contract liabilities
|
|
|
|
|
|
(
|
Operating lease liability
|
|
|
(
|
|
|
(
|
Litigation settlement contingency
|
|
|
|
|
|
|
Other non-current liabilities
|
|
|
|
|
|
|
Net cash used in operating activities
|
|
|
(
|
|
|
(
|
|
|
|
|
|
|
|
Cash flows from investing activities:
|
|
|
|
|
|
|
Purchases of property, machinery and equipment
|
|
|
|
|
|
(
|
Proceeds from sale of property, machinery and equipment
|
|
|
|
|
|
|
Purchases of intangible assets
|
|
|
(
|
|
|
(
|
Net cash provided by (used in) investing activities
|
|
|
|
|
|
(
|
|
|
|
|
|
|
|
Cash flows from financing activities:
|
|
|
|
|
|
|
Proceeds from issuance of convertible notes
|
|
|
|
|
|
|
Proceeds from exercise of stock options
|
|
|
|
|
|
|
Proceeds from employee stock purchase plan
|
|
|
|
|
|
|
Repurchase of Section 16 Officer shares for tax coverage exchange
|
|
|
(
|
|
|
(
|
Principal payments on loan payable
|
|
|
(
|
|
|
(
|
Payment of deferred offering costs
|
|
|
|
|
|
(
|
Payment for repurchase of common shares
|
|
|
|
|
|
(
|
Proceeds from issuance of common stock and related warrants
|
|
|
|
|
|
|
Payments for issuance costs related to common stock and related warrants
|
|
|
(
|
|
|
(
|
Net cash provided by (used in) financing activities
|
|
|
|
|
|
(
|
Decrease in cash, cash equivalents and restricted cash
|
|
|
(
|
|
|
(
|
Cash, cash equivalents and restricted cash, beginning of period
|
|
|
|
|
|
|
Cash, cash equivalents and restricted cash, end of period
|
|
|
$
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
Nine Months Ended September 30,
|
|||
|
|
|
2024
|
|
|
2023
|
Supplemental disclosure of non-cash investing and
financing activities
|
|
|
|
|
|
|
Purchases of intangible assets in accounts payable
and accrued expenses at period end
|
|
|
$
|
|
|
$
|
Issuance costs related to warrant modification
|
|
|
$
|
|
|
$
|
Issuance costs related to Placement Agent Warrants
|
|
|
$
|
|
|
$
|
Supplemental disclosure of cash flow information
|
|
|
|
|
|
|
Cash paid for interest
|
|
|
$
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
Fixed Assets
|
|
|
Estimated Useful Life
|
Computer equipment
|
|
|
|
Furniture and fixtures
|
|
|
|
Leasehold improvements
|
|
|
Lesser of estimated useful life or remaining lease term (
|
Machinery and equipment
|
|
|
|
|
|
|
|
•
|
Identification of the contract, or contracts, with a customer.
|
•
|
Identification of the performance obligations in the contract.
|
•
|
Determination of the transaction price.
|
•
|
Allocation of the transaction price to the performance obligations in the contract.
|
•
|
Recognition of revenue when, or as, the Company satisfies a performance obligation.
|
|
|
|
|
|
|
|
||||||
|
|
|
Three Months Ended
September 30,
|
|
|
Nine Months Ended
September 30,
|
||||||
(in thousands)
|
|
|
2024
|
|
|
2023
|
|
|
2024
|
|
|
2023
|
Transportation services
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
Hosted payload services
|
|
|
|
|
|
|
|
|
|
|
|
|
Forfeited customer deposits
|
|
|
|
|
|
|
|
|
|
|
|
|
Engineering project services
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
•
|
Level 1, observable inputs such as quoted prices in active markets;
|
•
|
Level 2, inputs other than the quoted prices in active markets that are observable either directly or indirectly; and
|
•
|
Level 3, unobservable inputs in which there is little or no market data, which requires that the Company develop its own
assumptions.
|
|
|
|
|
(in thousands)
|
|
|
Warrant Liability
(Level 3)
|
Balance, December 31, 2023
|
|
|
$
|
|
|
|
|
Balance, September 30, 2024
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30,
2024
|
|
|
December 31,
2023
|
Warrant term (years)
|
|
|
|
|
|
|
Volatility
|
|
|
|
|
|
|
Risk-free rate
|
|
|
|
|
|
|
Dividend yield
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
|
|
September 30,
2024
|
|
|
December 31,
2023
|
Prepaid launch costs, current
|
|
|
$
|
|
|
$
|
Prepaid research and development
|
|
|
|
|
|
|
Prepaid insurance and other assets
|
|
|
|
|
|
|
Total
|
|
|
$
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
|
|
September 30,
2024
|
|
|
December 31,
2023
|
Computer equipment
|
|
|
$
|
|
|
$
|
Leasehold improvements
|
|
|
|
|
|
|
Machinery and equipment
|
|
|
|
|
|
|
Property, machinery and equipment, gross
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
|
|
September 30,
2024
|
|
|
December 31,
2023
|
Less: accumulated depreciation
|
|
|
(
|
|
|
(
|
Property, machinery and equipment, net
|
|
|
$
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
|
|
Gross Value
|
|
|
Accumulated
Amortization
|
|
|
Net Value
|
|
|
Weighted Average Remaining
Amortization Period (In Years)
|
Patents/Intellectual Property
|
|
|
$
|
|
|
$(
|
|
|
$
|
|
|
|
Total
|
|
|
$
|
|
|
$(
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
|
|
Gross Value
|
|
|
Accumulated
Amortization
|
|
|
Net Value
|
|
|
Weighted Average Remaining
Amortization Period (In Years)
|
Patents/Intellectual Property
|
|
|
$
|
|
|
$(
|
|
|
$
|
|
|
|
Total
|
|
|
$
|
|
|
$(
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
|
|
|
Remainder of 2024
|
|
|
$
|
2025
|
|
|
|
2026
|
|
|
|
2027
|
|
|
|
2028
|
|
|
|
Thereafter
|
|
|
|
Total
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
Three Months Ended
September 30,
|
|
|
Nine Months Ended
September 30,
|
||||||
(in thousands)
|
|
|
2024
|
|
|
2023
|
|
|
2024
|
|
|
2023
|
Operating lease cost
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
Variable lease expense
|
|
|
|
|
|
|
|
|
|
|
|
|
Total lease expense
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
|
|
|
Remainder of 2024
|
|
|
$
|
2025
|
|
|
|
2026
|
|
|
|
2027
|
|
|
|
2028
|
|
|
|
Total lease payments
|
|
|
|
Less: Imputed interest
|
|
|
(
|
Present value of lease liabilities
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
|
|
September 30,
2024
|
|
|
December 31,
2023
|
Legal and other professional services
|
|
|
$
|
|
|
$
|
Compensation expense
|
|
|
|
|
|
|
Research and development projects
|
|
|
|
|
|
|
Other accrued liabilities
|
|
|
|
|
|
|
Total
|
|
|
$
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class A Warrants
|
|
|
Class B Warrants
|
|
|
Placement Agent
Warrants
|
Warrant term (years)
|
|
|
|
|
|
|
|
|
|
Volatility
|
|
|
|
|
|
|
|
|
|
Risk-free rate
|
|
|
|
|
|
|
|
|
|
Dividend yield
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant term (years)
|
|
|
|
Volatility
|
|
|
|
Risk-free rate
|
|
|
|
Dividend yield
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pre Modification
|
|
|
Post Modification
|
Warrant term (years)
|
|
|
|
|
|
|
Volatility
|
|
|
|
|
|
|
Risk-free rate
|
|
|
|
|
|
|
Dividend yield
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant term (years)
|
|
|
|
Volatility
|
|
|
|
Risk-free rate
|
|
|
|
Dividend yield
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pre Modification
|
|
|
Post Modification
|
Warrant term (years)
|
|
|
|
|
|
|
Volatility
|
|
|
|
|
|
|
Risk-free rate
|
|
|
|
|
|
|
Dividend yield
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands, except share-based data)
|
|
|
Total
Options
|
|
|
Weighted-Average
Exercise Price Per
Share
|
|
|
Weighted-Average
Remaining Contractual
Term (In Years)
|
|
|
Aggregate
Intrinsic
Value
|
Outstanding as of December 31, 2023
|
|
|
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands, except share-based data)
|
|
|
Total
Options
|
|
|
Weighted-Average
Exercise Price Per
Share
|
|
|
Weighted-Average
Remaining Contractual
Term (In Years)
|
|
|
Aggregate
Intrinsic
Value
|
Forfeitures
|
|
|
(
|
|
|
|
|
|
|
|
|
|
Outstanding as of September 30, 2024
|
|
|
|
|
|
$
|
|
|
|
|
|
$
|
Exercisable as of September 30, 2024
|
|
|
|
|
|
$
|
|
|
|
|
|
$
|
Vested and expected to vest as of September 30, 2024
|
|
|
|
|
|
$
|
|
|
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares
|
|
|
Weighted Average Grant Date
Fair Value (i.e. Share Price)
|
Outstanding as of December 31, 2023
|
|
|
|
|
|
$
|
Vested
|
|
|
(
|
|
|
|
Forfeited
|
|
|
(
|
|
|
|
Outstanding as of September 30, 2024
|
|
|
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
Three Months Ended
September 30,
|
|
|
Nine Months Ended
September 30,
|
||||||
(in thousands)
|
|
|
2024
|
|
|
2023
|
|
|
2024
|
|
|
2023
|
Research and development expenses
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
Selling, general and administrative expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
Three Months Ended
September 30,
|
|
|
Nine Months Ended
September 30,
|
||||||
(in thousands)
|
|
|
2024
|
|
|
2023
|
|
|
2024
|
|
|
2023
|
Options
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
RSUs & RSAs
|
|
|
|
|
|
|
|
|
|
|
|
|
ESPP
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
Three Months Ended
September 30,
|
|
|
Nine Months Ended
September 30,
|
||||||
|
|
|
2024
|
|
|
2023
|
|
|
2024
|
|
|
2023
|
Options and unvested stock units outstanding
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants outstanding
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible promissory notes
|
|
|
|
|
|
|
|
|
|
|
|
|
Contingent Sponsor Earnout Shares
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
|
|
|
Remainder of 2024
|
|
|
$
|
2025
|
|
|
|
Total
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
2023
|
|
|
December 31,
2022
|
ASSETS
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
|
$
|
|
|
$
|
Restricted cash, current
|
|
|
|
|
|
|
Insurance receivable
|
|
|
|
|
|
|
Prepaids and other current assets
|
|
|
|
|
|
|
Total current assets
|
|
|
|
|
|
|
Property, machinery and equipment, net
|
|
|
|
|
|
|
Intangible assets, net
|
|
|
|
|
|
|
Operating right-of-use asset
|
|
|
|
|
|
|
Deferred offering costs
|
|
|
|
|
|
|
Restricted cash, non-current
|
|
|
|
|
|
|
Other non-current assets
|
|
|
|
|
|
|
Total assets
|
|
|
$
|
|
|
$
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
Accounts payable
|
|
|
$
|
|
|
$
|
Accrued liabilities
|
|
|
|
|
|
|
Loan payable, current
|
|
|
|
|
|
|
Contract liabilities, current
|
|
|
|
|
|
|
Operating lease liability, current
|
|
|
|
|
|
|
Stock repurchase liability
|
|
|
|
|
|
|
Litigation settlement contingency
|
|
|
|
|
|
|
Other current liabilities
|
|
|
|
|
|
|
Total current liabilities
|
|
|
|
|
|
|
Contract liabilities, non-current
|
|
|
|
|
|
|
Loan Payable, non-current
|
|
|
|
|
|
|
Warrant liability
|
|
|
|
|
|
|
Operating lease liability, non-current
|
|
|
|
|
|
|
Other non-current liabilities
|
|
|
|
|
|
|
Total non-current liabilities
|
|
|
|
|
|
|
Total liabilities
|
|
|
|
|
|
|
Commitments and Contingencies (Note 12)
|
|
|
|
|
|
|
Stockholders’ equity:
|
|
|
|
|
|
|
Preferred stock, $
|
|
|
|
|
|
|
Class A common stock, $
|
|
|
|
|
|
|
Class B common stock, $
|
|
|
|
|
|
|
Additional paid-in capital
|
|
|
|
|
|
|
Accumulated deficit
|
|
|
(
|
|
|
(
|
Total stockholders’ equity
|
|
|
|
|
|
|
Total liabilities and stockholders’ equity
|
|
|
$
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
Year Ended
December 31,
|
|||
|
|
|
2023
|
|
|
2022
|
|
|
|
$
|
|
|
$
|
Cost of revenue
|
|
|
|
|
|
|
Gross profit
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
Research and development expenses
|
|
|
|
|
|
|
Selling, general and administrative expenses
|
|
|
|
|
|
|
Total operating expenses
|
|
|
|
|
|
|
Loss from operations
|
|
|
(
|
|
|
(
|
Other income (expense), net:
|
|
|
|
|
|
|
Change in fair value of warrant liability
|
|
|
|
|
|
|
Realized loss on disposal of assets
|
|
|
(
|
|
|
(
|
Interest income
|
|
|
|
|
|
|
Interest expense
|
|
|
(
|
|
|
(
|
Litigation settlement, net
|
|
|
|
|
|
(
|
Other income (expense)
|
|
|
(
|
|
|
|
Total other income (expense), net
|
|
|
(
|
|
|
(
|
Net loss
|
|
|
$(
|
|
|
$(
|
Net loss per share, basic and diluted
|
|
|
$(
|
|
|
$(
|
Weighted average shares outstanding, basic and diluted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
Common stock -
Class A
|
|
|
Additional
paid-in
capital
|
|
|
Accumulated
deficit
|
|
|
Total
stockholders’
equity
|
|||
|
|
|
Shares
|
|
|
Amount
|
|
||||||||
Balance, December 31, 2021
|
|
|
|
|
|
$
|
|
|
$
|
|
|
$(
|
|
|
$
|
Issuance of common stock upon exercise of stock
options
|
|
|
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
Issuance of common stock upon vesting of RSUs
|
|
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
Issuance of common stock upon purchase of ESPP
|
|
|
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
Share repurchase related to Section 16 Officer tax
coverage exchange
|
|
|
(
|
|
|
—
|
|
|
(
|
|
|
—
|
|
|
(
|
Stock-based compensation
|
|
|
—
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
Share repurchase valuation adjustment
|
|
|
—
|
|
|
—
|
|
|
(
|
|
|
—
|
|
|
(
|
Shares issued upon exercise of warrant
|
|
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
Net loss
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(
|
|
|
(
|
Balance, December 31, 2022
|
|
|
|
|
|
|
|
|
$
|
|
|
$(
|
|
|
$
|
Issuance of common stock upon exercise of stock
options
|
|
|
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
Issuance of common stock upon vesting of RSUs
|
|
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
Issuance of common stock upon purchase of ESPP
|
|
|
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
Share repurchase related to Section 16 Officer tax
coverage exchange
|
|
|
(
|
|
|
—
|
|
|
(
|
|
|
—
|
|
|
(
|
Issuance of common stock and related warrants in
registered offering, net of issuance costs
|
|
|
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
Issuance of common stock upon exercise of pre-funded
warrants
|
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
Issuance of common stock upon exercise of warrants
|
|
|
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
Stock-based compensation - stock options, RSAs, RSUs
|
|
|
—
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
Issuance of common stock for consulting services
|
|
|
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
Common stock issued in connection with reverse stock
split
|
|
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
Net loss
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(
|
|
|
(
|
Balance, December 31, 2023
|
|
|
|
|
|
$
|
|
|
$
|
|
|
$(
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
Years Ended December 31,
|
|||
|
|
|
2023
|
|
|
2022
|
Cash flows from operating activities:
|
|
|
|
|
|
|
Net loss
|
|
|
$(
|
|
|
$(
|
Adjustments to reconcile net loss to net cash used in operating
activities:
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
|
|
|
|
Amortization of debt discount and issuance costs
|
|
|
|
|
|
|
Amortization of right-of-use asset
|
|
|
|
|
|
|
Change in fair value of warrant liability
|
|
|
(
|
|
|
(
|
Impairment of prepaid launch costs
|
|
|
|
|
|
|
Write-off of deferred offering costs
|
|
|
|
|
|
|
Litigation settlement, net
|
|
|
|
|
|
|
Loss on disposal of fixed and intangible assets
|
|
|
|
|
|
|
Stock-based compensation expense
|
|
|
|
|
|
|
Issuance of common stock for consulting services
|
|
|
|
|
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
Prepaids and other current assets
|
|
|
(
|
|
|
(
|
Insurance receivable
|
|
|
|
|
|
|
Other non-current assets
|
|
|
|
|
|
(
|
Accounts payable
|
|
|
|
|
|
|
Accrued liabilities
|
|
|
(
|
|
|
(
|
Accrued interest
|
|
|
(
|
|
|
|
Other current liabilities
|
|
|
(
|
|
|
(
|
Contract liabilities
|
|
|
(
|
|
|
|
Operating lease liability
|
|
|
(
|
|
|
(
|
Litigation settlement contingency
|
|
|
(
|
|
|
|
Other non-current liabilities
|
|
|
|
|
|
|
Net cash used in operating activities
|
|
|
(
|
|
|
(
|
Cash flows from investing activities:
|
|
|
|
|
|
|
Purchases of property, machinery and equipment
|
|
|
(
|
|
|
(
|
Proceeds from sale of property, machinery and equipment
|
|
|
|
|
|
|
Purchases of intangible assets
|
|
|
(
|
|
|
(
|
Net cash used in investing activities
|
|
|
(
|
|
|
(
|
Cash flows from financing activities:
|
|
|
|
|
|
|
Proceeds from exercise of stock options
|
|
|
|
|
|
|
Proceeds from employee stock purchase plan
|
|
|
|
|
|
|
Proceeds from exercise of warrants
|
|
|
|
|
|
|
Repurchase of Section 16 Officer shares for tax coverage exchange
|
|
|
(
|
|
|
(
|
Principal payments on loan payable
|
|
|
(
|
|
|
(
|
Payment of deferred offering costs
|
|
|
|
|
|
(
|
Payment for repurchase of common shares
|
|
|
(
|
|
|
|
Proceeds from issuance of common stock and related warrants
|
|
|
|
|
|
|
Payments for issuance costs related to common stock and related warrants
|
|
|
(
|
|
|
|
Net cash provided by (used in) financing activities
|
|
|
|
|
|
(
|
Decrease in cash, cash equivalents and restricted cash
|
|
|
(
|
|
|
(
|
Cash, cash equivalents and restricted cash, beginning of year
|
|
|
|
|
|
|
Cash, cash equivalents and restricted cash, end of year
|
|
|
$
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
Years Ended December 31,
|
|||
|
|
|
2023
|
|
|
2022
|
Supplemental disclosure of non-cash investing and
financing activities
|
|
|
|
|
|
|
Purchases of property, machinery and equipment in
accounts payable and accrued expenses at period end
|
|
|
$
|
|
|
$
|
Purchases of intangible assets in accounts payable
and accrued expenses at year end
|
|
|
$
|
|
|
$
|
Issuance costs related to warrant modification
|
|
|
$
|
|
|
$
|
Stock repurchase liability fair value
|
|
|
$
|
|
|
$
|
Supplemental disclosure of cash flow information
|
|
|
|
|
|
|
Cash paid for interest
|
|
|
$
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
Fixed Assets
|
|
|
Estimated Useful Life
|
Computer equipment
|
|
|
|
Furniture and fixtures
|
|
|
|
Leasehold improvements
|
|
|
Lesser of estimated useful life or remaining lease term (
|
Machinery and equipment
|
|
|
|
|
|
|
|
•
|
Identification of the contract, or contracts, with a customer.
|
•
|
Identification of the performance obligations in the contract.
|
•
|
Determination of the transaction price.
|
•
|
Allocation of the transaction price to the performance obligations in the contract.
|
•
|
Recognition of revenue when, or as, the Company satisfies a performance obligation.
|
|
|
|
|
|||
|
|
|
Year Ended December 31,
|
|||
(in thousands)
|
|
|
2023
|
|
|
2022
|
Transportation services
|
|
|
$
|
|
|
$
|
Hosted payload services
|
|
|
|
|
|
|
Forfeited customer deposits
|
|
|
|
|
|
|
Engineering project services
|
|
|
|
|
|
|
Total revenue
|
|
|
$
|
|
|
$
|
|
|
|
|
|
|
|
•
|
Level 1, observable inputs such as quoted prices in active markets;
|
•
|
Level 2, inputs other than the quoted prices in active markets that are observable either directly or indirectly; and
|
•
|
Level 3, unobservable inputs in which there is little or no market data, which requires that the Company develop its own
assumptions.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
|
|
Level
|
|
|
Fair value as of
December 31,
2022
|
|
|
Payment of
Stock Repurchase
Liability
|
|
|
Change in
|
|
|
Fair value as of
December 31,
2023
|
Warrant Liability
|
|
|
3
|
|
|
$
|
|
|
$
|
|
|
$(
|
|
|
$
|
Stock Repurchase Liability
|
|
|
3
|
|
|
|
|
|
(
|
|
|
|
|
|
|
Total
|
|
|
|
|
|
$
|
|
|
$(
|
|
|
$(
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant term (years)
|
|
|
|
Volatility
|
|
|
|
Risk-free rate
|
|
|
|
Dividend yield
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
|
|
December 31,
2023
|
|
|
December 31,
2022
|
Prepaid launch costs, current
|
|
|
$
|
|
|
$
|
Prepaid research and development
|
|
|
|
|
|
|
Prepaid insurance and other assets
|
|
|
|
|
|
|
Total
|
|
|
$
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
|
|
December 31,
2023
|
|
|
December 31,
2022
|
Computer equipment
|
|
|
$
|
|
|
$
|
Leasehold improvements
|
|
|
|
|
|
|
Machinery and equipment
|
|
|
|
|
|
|
Construction in-progress
|
|
|
|
|
|
|
Property, machinery and equipment, gross
|
|
|
|
|
|
|
Less: accumulated depreciation
|
|
|
(
|
|
|
(
|
Property, machinery and equipment, net
|
|
|
$
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
|
|
Gross Value
|
|
|
Accumulated
Amortization
|
|
|
Net Value
|
|
|
Weighted Average Remaining
Amortization Period (In Years)
|
Patents/Intellectual Property
|
|
|
$
|
|
|
$(
|
|
|
$
|
|
|
|
Total
|
|
|
$
|
|
|
$(
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
|
|
Gross Value
|
|
|
Accumulated
Amortization
|
|
|
Net Value
|
|
|
Weighted Average Remaining
Amortization Period (In Years)
|
Patents/Intellectual Property
|
|
|
$
|
|
|
$(
|
|
|
$
|
|
|
|
Total
|
|
|
$
|
|
|
$(
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
|
|
|
2024
|
|
|
$
|
2025
|
|
|
|
2026
|
|
|
|
2027
|
|
|
|
2028
|
|
|
|
Thereafter
|
|
|
|
Total
|
|
|
$
|
|
|
|
|
|
|
|
|
|||
|
|
|
Year Ended December 31,
|
|||
(in thousands)
|
|
|
2023
|
|
|
2022
|
Operating lease cost
|
|
|
$
|
|
|
$
|
Variable lease expense
|
|
|
|
|
|
|
Short-term lease expense
|
|
|
|
|
|
|
Total lease expense
|
|
|
$
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
|
|
|
2024
|
|
|
$
|
2025
|
|
|
|
2026
|
|
|
|
2027
|
|
|
|
2028
|
|
|
|
Thereafter
|
|
|
|
Total lease payments
|
|
|
|
Less: Imputed interest
|
|
|
(
|
Present value of lease liabilities
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
|
|
December 31,
2023
|
|
|
December 31,
2022
|
Legal and other professional services
|
|
|
$
|
|
|
$
|
Compensation expense
|
|
|
|
|
|
|
Research and development projects
|
|
|
|
|
|
|
Other accrued liabilities
|
|
|
|
|
|
|
Total
|
|
|
$
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
November
Warrants
|
Warrant term (years)
|
|
|
|
Volatility
|
|
|
|
Risk-free rate
|
|
|
|
Dividend yield
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
Induced Warrants
|
|||
|
|
|
Before Modification
|
|
|
After Modification
|
Warrant term (years)
|
|
|
|
|
|
|
Volatility
|
|
|
|
|
|
|
Risk-free rate
|
|
|
|
|
|
|
Dividend yield
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
October
Warrants
|
Warrant term (years)
|
|
|
|
Volatility
|
|
|
|
Risk-free rate
|
|
|
|
Dividend yield
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
Before Modification
|
|
|
After Modification
|
|||
|
|
|
February Class A Warrants
and Series A Warrants
|
|
|
Series B Warrants
|
|
|
Modified Warrants
|
Warrant term (years)
|
|
|
|
|
|
|
|
|
|
Volatility
|
|
|
|
|
|
|
|
|
|
Risk-free rate
|
|
|
|
|
|
|
|
|
|
Dividend yield
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Series A Warrants
|
|
|
Series B Warrants
|
Warrant term (years)
|
|
|
|
|
|
|
Volatility
|
|
|
|
|
|
|
Risk-free rate
|
|
|
|
|
|
|
Dividend yield
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Before Modification
|
|
|
After Modification
|
Warrant term (years)
|
|
|
|
|
|
|
Volatility
|
|
|
|
|
|
|
Risk-free rate
|
|
|
|
|
|
|
Dividend yield
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant term (years)
|
|
|
|
Volatility
|
|
|
|
Risk-free rate
|
|
|
|
Dividend yield
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands, except share-based data)
|
|
|
Total
Options
|
|
|
Weighted-Average
Exercise Price
Per Share
|
|
|
Weighted-Average
Remaining Contractual
Term (In Years)
|
|
|
Aggregate
Intrinsic
Value
|
Outstanding as of December 31, 2022
|
|
|
|
|
|
$
|
|
|
|
|
|
|
Vested exercised
|
|
|
(
|
|
|
$
|
|
|
|
|
|
|
Forfeitures
|
|
|
(
|
|
|
$
|
|
|
|
|
|
|
Outstanding as of December 31, 2023
|
|
|
|
|
|
$
|
|
|
|
|
|
$
|
Exercisable as of December 31, 2023
|
|
|
|
|
|
$
|
|
|
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands, except share-based data)
|
|
|
Total
Options
|
|
|
Weighted-Average
Exercise Price
Per Share
|
|
|
Weighted-Average
Remaining Contractual
Term (In Years)
|
|
|
Aggregate
Intrinsic
Value
|
Vested and expected to vest as of December 31, 2023
|
|
|
|
|
|
$
|
|
|
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares
|
|
|
Weighted Average Grant Date
Fair Value (i.e. Share Price)
|
Outstanding as of December 31, 2022
|
|
|
|
|
|
$
|
Granted
|
|
|
|
|
|
|
Vested
|
|
|
(
|
|
|
|
Forfeited
|
|
|
(
|
|
|
|
Outstanding as of December 31, 2023
|
|
|
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
Year Ended December 31,
|
|||
(in thousands)
|
|
|
2023
|
|
|
2022
|
Research and development expenses
|
|
|
$
|
|
|
$
|
Selling, general and administrative expenses
|
|
|
|
|
|
|
Total
|
|
|
$
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
Year Ended December 31,
|
|||
(in thousands)
|
|
|
2023
|
|
|
2022
|
Options
|
|
|
$
|
|
|
$
|
RSUs & RSAs
|
|
|
|
|
|
|
ESPP
|
|
|
|
|
|
|
Performance Awards
|
|
|
|
|
|
(
|
Total
|
|
|
$
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
Year Ended December 31,
|
|||
|
|
|
2023
|
|
|
2022
|
Options and unvested stock units outstanding
|
|
|
|
|
|
|
Warrants outstanding
|
|
|
|
|
|
|
Contingent Sponsor Earnout Shares
|
|
|
|
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
|
|
|
2024
|
|
|
$
|
Total
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
||||||
(in thousands)
|
|
|
December 31, 2023
|
|
|
December 31, 2022
|
||||||
Tax provision (benefit) at U.S. statutory rate
|
|
|
$(
|
|
|
|
|
|
$(
|
|
|
|
State income taxes, net of federal benefit
|
|
|
$(
|
|
|
|
|
|
$
|
|
|
(
|
Non-deductible expenses
|
|
|
|
|
|
(
|
|
|
(
|
|
|
|
Change in value of equity instruments
|
|
|
(
|
|
|
|
|
|
(
|
|
|
|
Deferred adjustments
|
|
|
(
|
|
|
|
|
|
(
|
|
|
|
Other
|
|
|
(
|
|
|
|
|
|
|
|
|
|
Research and development credits
|
|
|
(
|
|
|
|
|
|
(
|
|
|
|
IRC Sec. 174
|
|
|
|
|
|
(
|
|
|
|
|
|
|
Uncertain tax positions
|
|
|
|
|
|
(
|
|
|
|
|
|
(
|
Change in valuation allowance
|
|
|
|
|
|
(
|
|
|
|
|
|
(
|
|
|
|
$
|
|
|
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
|
|
December 31,
2023
|
|
|
December 31,
2022
|
Deferred tax assets:
|
|
|
|
|
|
|
Net operating loss carryforwards
|
|
|
$
|
|
|
$
|
Start-up and Organization Costs
|
|
|
|
|
|
|
Capitalized research and development credits
|
|
|
|
|
|
|
Intangibles
|
|
|
|
|
|
|
Stock-based compensation
|
|
|
|
|
|
|
Research and development credits
|
|
|
|
|
|
|
Operating lease obligations
|
|
|
|
|
|
|
Accrued expenses and reserves
|
|
|
|
|
|
|
Property and equipment
|
|
|
|
|
|
|
Other
|
|
|
|
|
|
|
Total deferred tax assets before valuation allowance
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
|
|
December 31,
2023
|
|
|
December 31,
2022
|
Valuation allowance
|
|
|
(
|
|
|
(
|
Total deferred tax assets
|
|
|
$
|
|
|
$
|
Deferred Tax Liabilities:
|
|
|
|
|
|
|
Operating lease right-of-use assets
|
|
|
$(
|
|
|
$(
|
Total deferred tax liabilities
|
|
|
$(
|
|
|
$(
|
Net deferred tax assets
|
|
|
$
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands)
|
|
|
Gross unrecognized
tax benefits
|
Balance as of December 31, 2022
|
|
|
$
|
Increases related to prior tax positions
|
|
|
(
|
Increases related to current tax positions
|
|
|
|
Balance as of December 31, 2023
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
Amount
|
SEC registration fee
|
|
|
$3,148
|
FINRA filing fee
|
|
|
$7,500
|
Legal fees and expenses
|
|
|
$70,000
|
Accounting fees and expenses
|
|
|
$60,000
|
Miscellaneous
|
|
|
$10,000
|
Total
|
|
|
$150,648
|
|
|
|
|
|
|
|
|
Exhibit
Number
|
|
|
Description of Exhibit
|
|
|
Form of Placement Agency Agreement (incorporated by reference to
Exhibit 1.1 to the Company’s Registration Statement on Form S-1/A (Registration No. 333-283539) filed on December 10, 2024).
|
|
|
|
Agreement and Plan of Merger, dated as of October 7, 2020, by and
among Stable Road Acquisition Corp., Project Marvel First Merger Sub, Inc., Project Marvel Second Merger Sub, LLC, and Momentus Inc. (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on
October 7, 2020).
|
|
|
|
Amendment No. 1 to Agreement and Plan of Merger, dated March 5, 2021,
by and among Stable Road Acquisition Corp., Project Marvel First Merger Sub, Inc., Project Marvel Second Merger Sub, LLC, and Momentus Inc. (incorporated by reference to Exhibit 2.2 to the Company’s Registration Statement on Form S-4
(Registration No. 333-249787) filed on March 8, 2021).
|
|
|
|
Amendment No. 2 to Agreement and Plan of Merger, dated as of April 7,
2021, by and among Stable Road Acquisition Corp., Project Marvel First Merger Sub, Inc., Project Marvel Second Merger Sub, LLC, and Momentus Inc. (incorporated by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K
filed on April 8, 2021).
|
|
|
|
Amendment No. 3 to Agreement and Plan of Merger, dated as of June 29,
2021, by and among Stable Road Acquisition Corp., Project Marvel First Merger Sub, Inc., Project Marvel Second Merger Sub, LLC, and Momentus Inc. (incorporated by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K
filed on June 29, 2021).
|
|
|
|
Second Amended and Restated Certificate of Incorporation (incorporated
by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed on August 22, 2023)
|
|
|
|
Certificate of Amendment to Second Amended and Restated Certificate of
Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed on August 22, 2023).
|
|
|
|
Second Certificate of Amendment to Second Amended and Restated
Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed on December 10, 2024).
|
|
|
|
Amended and Restated Bylaws of the Company (incorporated by reference
to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed on August 18, 2021).
|
|
|
|
First Amendment to the Amended and Restated Bylaws of the Company
(incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on July 25, 2023).
|
|
|
|
Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1
to the Company’s Current Report on Form 8-K filed on September 16, 2024).
|
|
|
|
Form of Class A Warrant (incorporated by reference to Exhibit 4.2 to
the Company’s Current Report on Form 8-K filed on September 16, 2024).
|
|
|
|
Form of Class B Warrant (incorporated by reference to Exhibit 4.3 to
the Company’s Current Report on Form 8-K filed on September 16, 2024).
|
|
|
|
Securities Purchase Agreement (incorporated by reference to
Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on September 16, 2024).
|
|
|
|
Registration Rights Agreement (incorporated by reference to
Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on September 16, 2024).
|
|
|
|
Form of Placement Agent Common Stock Purchase Warrant (incorporated by
reference to Exhibit 4.6 to the Company’s Registration Statement on Form S-1 (Registration No. 333-282724) filed on October 18, 2024).
|
|
|
|
Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.7
to the Company’s Registration Statement on Form S-1/A (Registration No. 333-283539) filed on December 10, 2024).
|
|
|
|
Form of Warrant (incorporated by reference to Exhibit 4.8 to the
Company’s Registration Statement on Form S-1/A (Registration No. 333-283539) filed on December 10, 2024).
|
|
|
|
Form of Placement Agent Warrant.
|
|
|
|
Description of Securities
|
|
|
|
Opinion of Bradley Arant Boult Cummings LLP.
|
|
|
|
|
|
|
|
|
|
Exhibit
Number
|
|
|
Description of Exhibit
|
|
|
Amended and Restated Registration Rights Agreement, dated as of
August 12, 2021, by and among the Company, Sponsor, and certain other parties (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on August 18, 2021).
|
|
|
|
Form of Insider Letter (incorporated by reference to Exhibit 10.1 to
the Company’s Registration Statement on Form S-1 (Registration No. 333-233980) filed on October 10, 2019).
|
|
|
|
Form of Indemnification Agreement (incorporated by reference to
Exhibit 10.4 to the Company’s Current Report on Form 8-K filed on August 18, 2021).
|
|
|
|
Momentus 2021 Equity Incentive Plan (incorporated by reference to
Exhibit 10.5 to the Company’s Current Report on Form 8-K filed on August 18, 2021).
|
|
|
|
Form of option award agreement under 2021 Equity Incentive Plan
(incorporated by reference to Exhibit 10.6 to the Company’s Current Report on Form 8-K filed on August 18, 2021).
|
|
|
|
Form of RSU award agreement under 2021 Equity Incentive Plan
(incorporated by reference to Exhibit 10.7 to the Company’s Current Report on Form 8-K filed on August 18, 2021).
|
|
|
|
Momentus 2021 Employee Stock Purchase Plan (incorporated by reference
to Exhibit 10.8 to the Company’s Current Report on Form 8-K filed on August 18, 2021).
|
|
|
|
Momentus Inc. 2022 Inducement Equity Plan (incorporated by reference
to Exhibit 99.1 to the Company’s Registration Statement on Form S-8 filed on March 14, 2022).
|
|
|
|
First Amendment to the Momentus Inc. 2022 Inducement Equity Plan
(incorporated by reference to Exhibit 99.2 to the Company’s Registration Statement on Form S-8 (Registration No. 333-270761) filed on March 14, 2022).
|
|
|
|
Second Amendment to the Momentus Inc. 2022 Inducement Equity Plan
(incorporated by reference to Exhibit 99.3 to the Company’s Registration Statement on Form S-8 (Registration No. 333-272104) filed on May 19, 2023).
|
|
|
|
Form of option award agreement under 2022 Inducement Equity Plan
(incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed on May 11, 2022).
|
|
|
|
Form of RSU award agreement under 2022 Inducement Equity Plan
(incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q filed on May 11, 2022).
|
|
|
|
Employment Agreement of John C. Rood dated June 24, 2021 (incorporated
by reference to Exhibit 10.12 to the Company’s Current Report on Form 8-K filed on August 18, 2021).
|
|
|
|
Employment Agreement, by and between Momentus Inc. and Paul Ney, dated
September 17, 2021 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed October 4, 2021).
|
|
|
|
Director Compensation Policy (incorporated by reference to
Exhibit 10.15 to the Company’s Current Report on Form 8-K filed on August 18, 2021).
|
|
|
|
SEC Order in Administrative Proceeding 3-20393 (incorporated by
reference to Annex J to the Company’s Registration Statement on Form S-4 (Registration No. 333-249787) filed on July 21, 2021).
|
|
|
|
Momentus Inc. Amended and Restated 2018 Stock Plan and forms of award
agreement thereunder (incorporated by reference to Exhibit 10.11 to the Company’s Amendment No. 4 to Registration Statement on Form S-4 filed on July 21, 2021).
|
|
|
|
Form of Warrant Inducement Agreement (incorporated by reference to
Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on November 7, 2023).
|
|
|
|
Form of Securities Purchase Agreement (incorporated by reference to
Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on January 16, 2024).
|
|
|
|
Form of Securities Purchase Agreement (incorporated by reference to
Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on March 7, 2024).
|
|
|
|
Form of Change in Control Letter Agreement (incorporated by reference
to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q, filed on August 14, 2023).
|
|
|
|
Form of Secured Promissory Note (incorporated by reference to
Exhibit 10.22 to the Company’s Registration Statement on Form S-1 (Registration No. 333-282724) filed on October 18, 2024).
|
|
|
|
|
|
|
|
|
|
Exhibit
Number
|
|
|
Description of Exhibit
|
|
|
Secured Convertible Promissory Note, dated July 12, 2024, between
Space Infrastructure Ventures, LLC and Momentus Inc. (incorporated by reference to Exhibit 4.4 to the Company’s Quarterly Report on Form 10-Q, filed on November 14, 2024).
|
|
|
|
Secured Convertible Promissory Note, dated October 24, 2024, by and
between Space Infrastructures Ventures, LLC and Momentus Inc. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on October 28, 2024).
|
|
|
|
Form of Securities Purchase Agreement
|
|
|
|
Letter from the Company’s former independent accountant, dated
July 24, 2023 (incorporated by reference to Exhibit 16.1 to the Company’s Current Report on Form 8-K, filed on July 25, 2023).
|
|
|
|
List of Subsidiaries (incorporated by reference to Exhibit 21.1 to the
Company’s Current Report on Form 8-K filed on August 18, 2021).
|
|
|
|
Consent of Frank, Rimerman + Co. LLP, independent registered public
accounting firm.
|
|
|
|
Consent of Armanino LLP, independent registered public accounting firm
|
|
|
|
Consent of Bradley Arant Boult Cummings LLP (included in Exhibit 5.1).
|
|
|
|
Power of Attorney (included on the signature page to this registration
statement)
|
|
101.INS*
|
|
|
XBRL Instance Document – the instance document does not appear in the
Interactive Data File because XBRL tags are embedded within the Inline XBRL document.
|
101.CAL*
|
|
|
XBRL Taxonomy Extension Calculation Linkbase Document.
|
101.SCH*
|
|
|
XBRL Taxonomy Extension Schema Document.
|
101.DEF*
|
|
|
XBRL Taxonomy Extension Definition Linkbase Document.
|
101.LAB*
|
|
|
XBRL Taxonomy Extension Labels Linkbase Document.
|
101.PRE*
|
|
|
XBRL Taxonomy Extension Presentation Linkbase Document.
|
104*
|
|
|
Cover Page Interactive Data File (as formatted as Inline XBRL and
contained in Exhibit 101).
|
|
|
Filing Fee Table
|
|
|
|
|
|
#
|
Management contract or compensatory plan or arrangement
|
*
|
Filed herewith
|
†
|
Certain of the exhibits and schedules to this Exhibit List have been omitted in accordance with Regulation S-K Item 601(a)(5).
The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.
|
(a)
|
To file, during any period in which offers or sales are being made, a post-effective amendment to this registration
statement:
|
(i)
|
To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
|
(ii)
|
To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most
recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in
volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of
prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the
“Calculation of Registration Fee” table in the effective registration statement; and
|
(iii)
|
To include any material information with respect to the plan of distribution not previously disclosed in the registration
statement or any material change to such information in the registration statement, provided, however, that paragraphs (a)(1)(i), (ii), and (iii) of this section do not apply if the
|
(b)
|
That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall
be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
|
(c)
|
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold
at the termination of the offering.
|
(d)
|
For the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to
Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A (§ 230.430A of this chapter), shall be deemed to
be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or
made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first
use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.
|
(e)
|
That for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the
initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to
sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer
or sell such securities to such purchaser:
|
(i)
|
Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant
to Rule 424;
|
(ii)
|
Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or
referred to by the undersigned registrant;
|
(iii)
|
The portion of any other free writing prospectus relating to the offering containing material information about the
undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and
|
(iv)
|
Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.
|
(f)
|
That, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report
pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the
registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
|
(g)
|
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers
and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as
expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director,
officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant
will, unless in the
|
(h)
|
That:
|
(1)
|
For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of
prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be
part of this registration statement as of the time it was declared effective.
|
(2)
|
For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a
form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
|
|
|
|
|
|||
|
|
|
MOMENTUS INC.
|
|||
|
|
|
|
|
|
|
|
|
|
By:
|
|
|
/s/ John C. Rood
|
|
|
|
Name:
|
|
|
John C. Rood
|
|
|
|
Title:
|
|
|
Chief Executive Officer
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
|
/s/ Lon Ensler
|
|
|
|
Name:
|
|
|
Lon Ensler
|
|
|
|
Title:
|
|
|
Interim Chief Financial Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Signature
|
|
|
Title
|
|
|
Date
|
|
|
|
|
|
|
|
/s/ John C. Rood
|
|
|
Chief Executive Officer and Director
(Principal Executive Officer)
|
|
|
January 21, 2025
|
John C. Rood
|
|
|
|
|||
|
|
|
|
|
|
|
/s/ Lon Ensler
|
|
|
Interim Chief Financial Officer
(Principal Financial and Accounting Officer)
|
|
|
January 21, 2025
|
Lon Ensler
|
|
|
|
|||
|
|
|
|
|
|
|
/s/ Chris Hadfield
|
|
|
Director
|
|
|
January 21, 2025
|
Chris Hadfield
|
|
|
|
|||
|
|
|
|
|
|
|
/s/ Brian Kabot
|
|
|
Director
|
|
|
January 21, 2025
|
Brian Kabot
|
|
|
|
|||
|
|
|
|
|
|
|
/s/ Mitchel B. Kugler
|
|
|
Director
|
|
|
January 21, 2025
|
Mitchel B. Kugler
|
|
|
|
|||
|
|
|
|
|
|
|
/s/ Victorino Mercado
|
|
|
Director
|
|
|
January 21, 2025
|
Victorino Mercado
|
|
|
|
|||
|
|
|
|
|
|
|
/s/ Kimberly A. Reed
|
|
|
Director
|
|
|
January 21, 2025
|
Kimberly A. Reed
|
|
|
|
|||
|
|
|
|
|
|
|
/s/ Linda J. Reiners
|
|
|
Director
|
|
|
January 21, 2025
|
Linda J. Reiners
|
|
|
|
|||
|
|
|
|
|
|
|
Warrant Shares: [___]
|
Original Issuance Date: [___]
|
(A) =
|
as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof
on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in Rule 600(b)(68) of Regulation NMS promulgated under the
federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the
principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder’s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during “regular trading hours” on a Trading Day and is delivered
within two (2) hours thereafter (including until two (2) hours after the close of “regular trading hours” on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of
such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of “regular trading hours” on such Trading Day;
|
|
(B) =
|
the Exercise Price of this Warrant, as adjusted hereunder; and
|
|
(X) =
|
the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless
exercise.
|
i.
|
Delivery of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder’s or its designee’s balance
account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting
the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered in the Company’s share
register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the
earlier of (A) the earlier of (i) one (1) Trading Day and (ii) the number of days comprising the Standard Settlement Period, in each case after the delivery to the Company of the Notice of Exercise and (B) one (1) Trading Day after
delivery of the aggregate Exercise Price to the Company (such date, the “Warrant Share Delivery Date”). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of
record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless
exercise) is received by the Warrant Share Delivery Date. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the
Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day
(increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such
exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, “Standard Settlement Period” means the standard
settlement period, expressed in a number of Trading Days, on the Company’s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.
|
ii.
|
Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the
Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this
Warrant.
|
iii.
|
Rescission Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right
to rescind such exercise.
|
iv.
|
Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the
Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open
market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such
exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so
purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order
giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case
such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example,
if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation
of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in
respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including,
without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.
|
v.
|
No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be
entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the
next whole share.
|
vi.
|
Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of
which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that in the
event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the
Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any
Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.
|
vii.
|
Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.
|
i.
|
Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise
Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.
|
ii.
|
Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a
redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the
approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all
of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or
winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of
the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption,
rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date
on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to
exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any
defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material,
non-public information regarding the Company or any of the Company’s subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to
exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.
|
i.
|
by operation of law or by reason of reorganization of the Company;
|
ii.
|
to any FINRA member firm participating in the offering and the officers or partners thereof, if all securities so transferred remain subject to the lock‑up restriction in this Section 4(a) for the remainder of the time period;
|
iii.
|
if the aggregate amount of securities of the Company held by the Holder or related person do not exceed 1% of the securities being offered;
|
iv.
|
that is beneficially owned on a pro-rata basis by all equity owners of an investment fund, provided that no participating member manages or otherwise directs investments by the fund, and participating members in the aggregate do
not own more than 10% of the equity in the fund; or
|
v.
|
the exercise or conversion of any security, if all securities received remain subject to the lock-up restriction in this Section 4(a) for the remainder of the time period.
|
MOMENTUS, INC.
|
||
By:
|
||
Name: John Rood
|
||
Title: Chief Executive Officer
|
Name of Investing Entity:
|
Signature of Authorized Signatory of Investing Entity:
|
Name of Authorized Signatory:
|
Title of Authorized Signatory:
|
Date:
|
Name:
|
|||
(Please Print)
|
|||
Address:
|
|||
(Please Print)
|
|||
Phone Number:
|
|||
Email Address:
|
|||
Dated: _______________ __, ______
|
|||
Holder’s Signature:
|
|||
Holder’s Address:
|
Very truly yours,
|
|
/s/ Bradley Arant Boult Cummings, LLP
|
(i) |
this Agreement duly executed by the Company;
|
(ii) |
a legal opinion of Company Counsel in a form reasonably acceptable to the Placement Agent;
|
(iii) |
the Company’s wire instructions, on Company letterhead and executed by the Chief Executive Officer or Chief Financial Officer;
|
(iv) |
subject to the last sentence of Section 2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver on an expedited basis via The
Depository Trust Company Deposit or Withdrawal at Custodian system (“DWAC”) Shares equal to the Purchaser’s Subscription Amount divided by the Per Unit Purchase Price, registered in the name of the Purchaser;
|
(v) |
if applicable, a Pre-Funded Warrant registered in the name of each Purchaser to purchase up to a number of shares of Common Stock equal to the difference between (A) the Purchaser’s
Subscription Amount applicable to the Pre-Funded Warrants divided by the Pre-Funded Warrant Purchase Price and (B) the number of Shares otherwise issuable to each Purchaser that would cause the Purchaser’s beneficial ownership of Common Stock
to be more than the Beneficial Ownership Limitation with an exercise price equal to $0.00001 per share of Common Stock, subject to adjustment therein;
|
(vi) |
the Preliminary Prospectus and the Prospectus (which may be delivered in accordance with Rule 172 under the Securities Act);
|
(vii) |
a Common Warrant registered in the name of each Purchaser to purchase up to a number of shares of Common Stock equal to 100% of the Purchaser’s Shares, with an exercise price equal to
$[__], subject to adjustment therein;
|
(viii) |
an Officer’s Certificate, in form and substance reasonably satisfactory to the Placement Agent;
|
(ix) |
a Secretary’s Certificate, in form and substance reasonably satisfactory to the Placement Agent; and
|
(x) |
the Lock-Up Agreements duly executed by each executive officer and director of the Company.
|
(i) |
this Agreement duly executed by such Purchaser; and
|
(ii) |
the Purchaser’s Subscription Amount, which shall be made available for DVP settlement with the Company or its designees.
|
(i) |
from the Auditor a cold comfort letter containing statements and information of the type customarily included in accountants’ comfort letters with respect to the financial statements
and certain financial information contained in the Registration Statement, the Preliminary Prospectus and the Prospectus, or any Issuer Free Writing Prospectus, addressed to the Placement Agent and in form and substance satisfactory in all
respects to the Placement Agent, dated as of the date of this Agreement; and
|
(ii) |
from the Chief Financial Officer of the Company, a certificate certifying as to certain financial matters set forth therein and in form and substance satisfactory in all respects to the
Placement Agent, dated as of the date of this Agreement.
|
(i) |
from the Auditor a letter, dated as of the Closing Date, to the effect that the Auditor reaffirms the statements made in the letter furnished pursuant to Section 2.2(c)(i); and
|
(ii) |
from the Chief Financial Officer of the Company, a certificate, dated as of the Closing Date, to the effect that the Chief Financial Officer of the Company reaffirms the statements made
in the certificate furnished pursuant to Section 2.2(c)(ii).
|
(i) |
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) when made and on the
Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in which case they shall be accurate as of such date);
|
(ii) |
all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed; and
|
(iii) |
the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.
|
(i) |
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) when made and on the
Closing Date of the representations and warranties of the Company contained herein (unless as of a specific date therein in which case they shall be accurate as of such date);
|
(ii) |
all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;
|
(iii) |
the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;
|
(iv) |
there shall have been no Material Adverse Effect with respect to the Company since the date hereof; and
|
(v) |
from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company’s principal Trading Market, and, at any time prior
to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such service, or on any
Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities nor shall there have occurred any material outbreak or escalation of hostilities or other national or international
calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of the Purchaser, makes it impracticable or inadvisable to purchase the Securities at the
Closing.
|
MOMENTUS INC.
|
Address for Notice:
|
||
3901 N. First Street
San Jose, CA 95134
|
|||
By:
|
Fax:
|
||
Name: John Rood
|
E-mail: john.rood@momentus.space
|
||
Title: Chief Executive Officer
|
|||
With a copy to (which shall not constitute notice):
|
|||
Bradley Arant Boult Cummings LLP
One Federal Place
1819 5th Avenue N
Birmingham, AL 35203
Attn: Stephen Hinton
Email: shinton@bradley.com
|
/s/ Armanino LLP
|
|
ArmaninoLLP
|
|
San Ramon, California
|
Security
Type
|
Security
Class
Title
|
Fee
Calculation
Rule
|
Amount
Registered(1)
|
Proposed
Maximum
Offering
Price Per
Share(2)
|
Proposed
Maximum
Aggregate
Offering Price (1)(2)(3)
|
Fee
Rate
|
Amount of
Registration
Fee
|
||||||||
Fees to be Paid
|
Equity
|
Common stock (4)
|
457(o)
|
—
|
—
|
$10,005,000
|
0.00015310
|
$1,531.77
|
|||||||
Fees to be Paid
|
Equity
|
Pre-funded warrants (4)(5)
|
457(g)
|
—
|
—
|
Included above
|
—
|
—
|
|||||||
Fees to be Paid
|
Equity
|
Common stock issuable upon exercise of pre-funded warrants (4)
|
457(o)
|
—
|
—
|
Included above
|
—
|
—
|
|||||||
Fees to be Paid
|
Equity
|
Warrants (5)
|
457(g)
|
—
|
—
|
—
|
—
|
—
|
|||||||
Fees to be Paid
|
Equity
|
Placement agent warrants (5)
|
457(g)
|
—
|
—
|
—
|
—
|
—
|
|||||||
Fees to be Paid
|
Equity
|
Common stock issuable upon exercise of warrants
|
457(o)
|
—
|
—
|
$10,005,000
|
0.00015310
|
$1,531.77
|
|||||||
Fees to be Paid
|
Equity
|
Common stock issuable upon exercise of placement agent warrants
|
457(o)
|
—
|
—
|
$550,275
|
0.00015310
|
$84.25
|
|||||||
Total Offering Amounts
|
$20,560,275
|
$3,147.79
|
|||||||||||||
Total Fee Previously Paid
|
—
|
||||||||||||||
Total Fee Offsets
|
$3,147.79 (6)
|
||||||||||||||
Net Fee Due
|
$—
|
Registrant
or Filer
Name
|
Form
or
Filing
Type
|
File
Number
|
Initial
Filing
Date
|
Filing
Date
|
Fee Offset
Claimed
|
Security
Type
Associated
with Fee
Offset
Claimed
|
Security
Title
Associated
with Fee
Offset
Claimed
|
Unsold
Securities
Associated
with Fee
Offset
Claimed
|
Unsold
Aggregate
Offering
Amount
Associated
with Fee
Offset Claimed
|
Fee Paid
with Fee
Offset
Source
|
|||||||||||||
Rule 457(p)
|
|||||||||||||||||||||||
Fee Offset Claims
|
Form S-1
|
333-
283539
|
December 2, 2024
|
$3,147.79
|
Equity
|
Class A common stock, $0.00001 par
value per share
|
N/A
|
$41,218,158.07
|
—
|
||||||||||||||
Fee-Offset Sources
|
Momentus, Inc.
|
Form S-1
|
333-
283539
|
December 2, 2024
|
—
|
—
|
—
|
—
|
—
|
$3,147.79
|
(1) |
Estimated solely for purposes of calculating the registration fee in accordance with Rule 457(o) under the Securities Act of 1933, as amended (the “Securities Act”).
|
(2) |
Pursuant to Rule 416 under the Securities Act, the securities registered hereby also include an indeterminate number of additional securities as may from time to time become issuable by reason of stock splits, stock
dividends, recapitalizations, or other similar transactions.
|
(3) |
Includes the price of additional shares of common stock that may be issued upon exercise of the over-allotment option granted to the underwriters to cover over-allotments, if any.
|
(4) |
The proposed maximum aggregate offering price of the common stock will be reduced on a dollar-for-dollar basis based on the offering price of any pre-funded warrants issued in the offering, and the proposed maximum
aggregate offering price of the pre-funded warrants to be issued in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any common stock issued in the offering. Accordingly, the proposed maximum aggregate
offering price of the common stock, and pre-funded warrants (including the common stock issuable upon exercise of the pre-funded warrants), if any, is $8,000,000.
|
(5) |
No fee pursuant to Rule 457(g) of the Securities Act.
|
(6) |
The Registrant previously filed a Registration Statement on Form S-1 with the Securities and Exchange Commission on December 2, 2024 (File No.
333-283539), as amended, which was declared effective on December 17, 2024 (the “Initial Registration Statement”), that registered an aggregate of $46,218,158.07 of securities to be offered by the Registrant, for which the Registrant paid a
filing fee of $7,076.00. On December 18, 2024, the Registrant completed a primary offering of $5,000,000 of its securities registered under the Initial Registration Statement and $41,218,158.07 of the securities remain unsold, leaving
$5,530.58 in previously paid fees available for future offset. The Registrant filed a Registration Statement on Form S-1 with the Securities and Exchange Commission on December 11, 2024 (File No. 333-283727), as amended, which was declared
effective on January 2, 2025 (the “Subsequent Registration Statement”). In connection with the filing of the Subsequent Registration Statement, $122.24 of the fees available for offset were used towards the filing fee of the Subsequent
Registration Statement. In accordance with Rule 457(p) under the Securities Act, the Registrant is using $3,147.79 of the unused filing fees to offset the filing fee payable in connection with this filing. Accordingly no registration fee of
is due to be paid at this time. Concurrently with the effectiveness of this registration statement, any offering of unsold securities pursuant to the Prior Registration Statement is hereby terminated.
|